APPROVED DRUG PRODUCTS
With Therapeutic Equivalence Evaluations

The "Orange Book"

FDA data supplied by DrugPatentWatch.com

CUMULATIVE SUPPLEMENT 2
FEBRUARY 2014



APPROVED DRUG PRODUCTS

WITH THERAPEUTIC EQUIVALENCE EVALUATIONS

34th EDITION

Department of Health and Human Services
Food and Drug Administration
Center for Drug Evaluation and Research
Office of Medical Products and Tobacco
Office of Generic Drugs

2014

Prepared By
Office of Generic Drugs
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Food and Drug Administration

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

34th EDITION

Cumulative Supplement 2

February 2014

CONTENTS

PAGE

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

34th EDITION

CUMULATIVE SUPPLEMENT 2
February 2014

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 34th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; over-the-counter (OTC) drug products that require approved applications as a condition of marketing; drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research; and products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, or have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of this Edition List will then be added to the "Discontinued Drug Product List" appearing in the next Edition. The current Annual Edition Section 2.1, How To Use The Drug Product Lists, describes the layout and usage of the List.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol **>A>**. The Patent and Exclusivity List new additions are indicated by the symbol **>A>** to the left of Patent Number or Exclusivity Code. The **>A>** symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol **>D>** (DELETE) to the left of the line. The information line with the **>D>** symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month’s second work week (e.g., November’s supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.

- All product changes received and processed as of the date of publication.
  - o Refer to CS Section 1.8 Cumulative Supplement Legend for types of changes
  - o Discontinued products will be processed as of the date of publication. There will be circumstances where a product is discontinued in one month, however, it will be reported in a different month's CS. For example, the Orange Book Staff received a letter November 7 that the product has been discontinued from manufacturing and marketing. The Orange Book subsequently publishes the October CS on November 14. The product will show in the October CS that it is discontinued even though the date of discontinuance is the day that the Orange Book Staff receives notification (November 7).

- New Drug Application (NDA) approvals appear in the CS month they were approved.

- Patent information, also updated daily in the EOB, is current to the date of publication.

- Exclusivity information is updated monthly and current to the date of publication.

Every effort is made to ensure the Cumulative Supplement is current and accurate. Applicant holders are requested to inform the FDA Orange Book Staff (OBS) of any changes or corrections. The OBS can be contacted by email at drugproducts@fda.hhs.gov. Send Changes by FAX: 240-276-8974; mail to:

FDA/CDER Orange Book Staff
Office of Generic Drugs, HFD-610
7620 Standish Place
Rockville, MD 20855-2773

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

FORMER APPLICANT NAME (FORMER ABBREVIATED NAME)	NEW APPLICANT NAME (NEW ABBREVIATED NAME)
WEST WARD INC (WEST WARD)	HIKMA PHARMACEUTICALS (HIKMA PHARMS)
WEST WARD PHARMACEUTICAL CORP (WEST WARD PHARMS CORP)	HIKMA PHARMACEUTICALS (HIKMA PHARMS)
WEST WARD PHARMACEUTICAL CORP (WEST WARD PHARMS)	HIKMA PHARMACEUTICALS (HIKMA PHARMS)

1.4 LEVOTHYROXINE SODIUM

Because there are multiple reference listed drugs of levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character TE codes may be potentially confusing and inadequate for these drug products. Accordingly, FDA provides the following explanation and chart of therapeutic equivalence evaluations for levothyroxine sodium drug products.

Levothyroxine Sodium (Mylan ANDA 76187) and Levo-T (Alara NDA 21342) tablets have been determined to be therapeutically equivalent to corresponding strengths of Unithroid (Jerome Stevens NDA 021210) tablets. Levo-T (Alara NDA 021342), Levothyroxine Sodium (Mylan ANDA 76187), Unithroid (Jerome Stevens NDA 021210), and Levothyroxine Sodium (Merck KGAA ANDA 76752)tablets have been determined to be therapeutically equivalent to corresponding strengths of Synthroid (Abbott NDA 021402) tablets.

Levo-T (Alara NDA 021342), Unithroid (Jerome Stevens NDA 021210), Levothyroxine Sodium (Mylan ANDA 076187), and Levothyroxine Sodium (Merck KGAA ANDA 76752) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levoxyl (King Pharms NDA 021301) tablets.

Levothyroxine Sodium (Mylan ANDA 76187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levothroid (Lloyd NDA 021116) tablets.

The chart outlines TE codes for all 0.025mg products. Other product strengths may be similar. Therapeutic equivalence has been established between products that have the same AB+number TE code. More than one TE code may apply to some products. One common TE code indicates therapeutic equivalence between products.

Trade Name	Applicant	Potency	TE Code	Appl No	Product No
UNITHROID	STEVENS J	0.025MG	AB1	21210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB1	76187	001
LEVOXYL	KING PHARMS	0.025MG	AB1	21301	001
SYNTHROID	ABBOTT	0.025MG	AB1	21402	001
LEVO-T	ALARA PHARM	0.025MG	AB1	21342	001
SYNTHROID	ABBOTT	0.025MG	AB2	21402	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB2	76187	001
LEVO-T	ALARA PHARM	0.025MG	AB2	21342	001
UNITHROID	STEVENS J	0.025MG	AB2	21210	001
LEVOXYL	KUNG PHARMS	0.025MG	AB3	21301	001
LEVO-T	ALARA PHARM	0.025MG	AB3	21342	001
UNITHROID	STEVENS J	0.025MG	AB3	21210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB3	76187	001
LEVOTHROID	LLOYD	0.025MG	AB4	21116	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB4	76187	001

1.5 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable

Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic Equivalence Evaluations, ADP) from the U.S. Government Printing Office: http://bookstore.gpo.gov; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, http://www.fda.gov/opacom/morechoices/fdaforms/default.html.

The current listing of the Orphan Product Designations and Approvals is available at http://www.fda.gov/orphan/designat/list.htm.

1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 2012) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST
COUNTS CUMULATIVE BY QUARTER

CATEGORIES COUNTED	DEC 2013	MAR 2014	JUN 2014	SEPT 2014	DEC 2014
DRUG PRODUCTS LISTED	15711				
SINGLE SOURCE	2517 (16.0%)				
MULTISOURCE	13194 (84.0%)				
THERAPEUTICALLY EQUIVALENT	13055 (83.1%)				
NOT THERAPEUTICALLY EQUIVALENT	139 (0.9%)				
EXCEPTIONS[1]	78 (0.5%)				
NEW MOLECULAR ENTITIES APPROVED	20				
NUMBER OF APPLICANTS	866				

[1]Amino acid-containing products of varying composition (see Introduction, page xx of the List).

1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route and then by trade name.

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by “N” is a New Drug Application (NDA or innovator). The application number preceded by an “A” is an Abbreviated New Drug Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form; route(s), new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be proceeded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval usually in the supplement month.
CAHN	Applicant holder firm name has changed.
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration.

CFTG	Change. A first time generic for the innovator product. A TE Code is added.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug.
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition.

ACAMPROSATE CALCIUM

TABLET, DELAYED RELEASE;ORAL

ACAMPROSATE CALCIUM

>A>	AB	MYLAN PHARMS INC	333MG	A200142	001	Mar 11, 2014	Feb	NEWA

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

TABLET;ORAL

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

		@ WATSON LABS	500MG;50MG;40MG	A040267	001	Jul 30, 1998	Jan	DISC

ACETAMINOPHEN; HYDROCODONE BITARTRATE

SOLUTION;ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

>D>	AA	BOCA PHARMA LLC	325MG/15ML;7.5MG/15ML	A040894	001	Jul 19, 2011	Feb	CAHN
		@ MALLINCKRODT	500MG/15ML;7.5MG/15ML	A040418	001	Jun 27, 2001	Jan	DISC
>A>	AA	VINTAGE PHARMS	325MG/15ML;7.5MG/15ML	A040894	001	Jul 19, 2011	Feb	CAHN

TABLET;ORAL

ANEXSIA

		@ MALLINCKRODT	500MG;5MG	A089160	001	Apr 23, 1987	Jan	DISC
		@	750MG;10MG	A040468	001	Oct 31, 2002	Jan	DISC

ANEXSIA 7.5/650

		@ MALLINCKRODT	650MG;7.5MG	A089725	001	Sep 30, 1987	Jan	DISC

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

>D>	AA	BOCA PHARMA LLC	300MG;5MG	A090415	001	Jan 24, 2011	Feb	CAHN
>D>	AA		300MG;7.5MG	A090415	002	Jan 24, 2011	Feb	CAHN
>D>	AA		300MG;10MG	A090415	003	Jan 24, 2011	Feb	CAHN
		@ MALLINCKRODT	500MG;5MG	A040084	002	Jun 01, 1995	Jan	DISC
		@	500MG;7.5MG	A040201	001	Feb 27, 1998	Jan	DISC
		@	500MG;10MG	A040201	002	Feb 27, 1998	Jan	DISC
		@	650MG;10MG	A040084	004	Oct 16, 1996	Jan	DISC
		@	660MG;10MG	A040084	003	Jul 29, 1996	Jan	DISC
		@	750MG;7.5MG	A040084	001	Jun 01, 1995	Jan	DISC
>A>	AA	VINTAGE PHARMS	300MG;5MG	A090415	001	Jan 24, 2011	Feb	CAHN
>A>	AA		300MG;7.5MG	A090415	002	Jan 24, 2011	Feb	CAHN
>A>	AA		300MG;10MG	A090415	003	Jan 24, 2011	Feb	CAHN
		@	650MG;7.5MG	A040155	001	Apr 14, 1997	Jan	DISC
		@	750MG;7.5MG	A040157	001	Apr 12, 1996	Jan	DISC
		@ WATSON LABS	500MG;7.5MG	A081080	001	Aug 30, 1991	Jan	DISC
		@	750MG;7.5MG	A081083	001	Aug 30, 1991	Jan	DISC

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

CAPSULE;ORAL

OXYCODONE AND ACETAMINOPHEN

		@ MALLINCKRODT	500MG;5MG	A040257	001	Aug 04, 1998	Jan	DISC
		@ WATSON LABS	500MG;5MG	A040234	001	Oct 30, 1997	Jan	DISC

TABLET;ORAL

OXYCODONE AND ACETAMINOPHEN

		@ WATSON LABS	500MG;7.5MG	A040371	001	Dec 29, 2000	Jan	DISC
		@	650MG;10MG	A040371	002	Dec 29, 2000	Jan	DISC

PERCOCET

		@ VINTAGE PHARMS LLC	500MG;7.5MG	A040341	001	Jul 26, 1999	Jan	DISC
		@	650MG;10MG	A040341	002	Jul 26, 1999	Jan	DISC

ACETYLCYSTEINE

SOLUTION;INHALATION, ORAL

ACETYLCYSTEINE

	AN	INNOPHARMA LICENSING	10%	A204674	001	Feb 11, 2014	Jan	NEWA

ACYCLOVIR

CAPSULE;ORAL

ACYCLOVIR

>A>	AB	CADILA PHARMS LTD	200MG	A201445	001	Mar 06, 2014	Feb	NEWA

ACYCLOVIR SODIUM

INJECTABLE;INJECTION

ACYCLOVIR SODIUM

>D>	AP	BEDFORD	EQ 1GM BASE/VIAL	A074596	001	Apr 22, 1997	Feb	CRLD
>A>		+	EQ 1GM BASE/VIAL	A074596	001	Apr 22, 1997	Feb	CRLD
>D>	AP	HIKMA MAPLE	EQ 1GM BASE/VIAL	A074913	002	Oct 15, 1997	Feb	DISC
>A>		@	EQ 1GM BASE/VIAL	A074913	002	Oct 15, 1997	Feb	DISC

INJECTABLE;INJECTION
ACYCLOVIR SODIUM

>D>	AP		EQ 500MG BASE/VIAL	A074913	001	Oct 15, 1997	Feb DISC
>A>		@	EQ 500MG BASE/VIAL	A074913	001	Oct 15, 1997	Feb DISC

ADENOSINE

INJECTABLE;INJECTION
ADENOSINE

>A>	AP	AGILA SPECLTS	3MG/ML	A078686	001	May 13, 2009	Feb CAHN
>D>	AP	STRIDES ARCOLAB LTD	3MG/ML	A078686	001	May 13, 2009	Feb CAHN

ALPRAZOLAM

TABLET;ORAL
ALPRAZOLAM

>D>	AB	BOCA PHARMA LLC	0.25MG	A090248	001	Sep 17, 2010	Feb CAHN
>D>	AB		0.5MG	A090248	002	Sep 17, 2010	Feb CAHN
>D>	AB		1MG	A090248	003	Sep 17, 2010	Feb CAHN
>D>	AB		2MG	A090248	004	Sep 17, 2010	Feb CAHN
>A>	AB	VINTAGE PHARMS	0.25MG	A090248	001	Sep 17, 2010	Feb CAHN
>A>	AB		0.5MG	A090248	002	Sep 17, 2010	Feb CAHN
>A>	AB		1MG	A090248	003	Sep 17, 2010	Feb CAHN
>A>	AB		2MG	A090248	004	Sep 17, 2010	Feb CAHN

TABLET, EXTENDED RELEASE;ORAL
ALPRAZOLAM

	AB	ANI PHARMS INC	0.5MG	A077725	001	Jul 31, 2006	Jan CAHN
		@	0.5MG	A077979	001	Feb 28, 2007	Jan CAHN
	AB		1MG	A077725	002	Jul 31, 2006	Jan CAHN
		@	1MG	A077979	002	Feb 28, 2007	Jan CAHN
	AB		2MG	A077725	004	Jul 31, 2006	Jan CAHN
		@	2MG	A077979	003	Feb 28, 2007	Jan CAHN
	AB		3MG	A077725	003	Jul 31, 2006	Jan CAHN
		@	3MG	A077979	004	Feb 28, 2007	Jan CAHN

AMANTADINE HYDROCHLORIDE

CAPSULE;ORAL
AMANTADINE HYDROCHLORIDE

>D>	AB	SANDOZ	100MG	A071293	001	Feb 18, 1987	Feb CRLD
>A>	AB	+	100MG	A071293	001	Feb 18, 1987	Feb CRLD
>D>	AB	+ USL PHARMA	100MG	A070589	001	Aug 05, 1986	Feb CRLD
>A>	AB		100MG	A070589	001	Aug 05, 1986	Feb CRLD

AMLODIPINE BESYLATE

TABLET;ORAL
AMLODIPINE BESYLATE

>D>	AB	PURACAP PHARM	EQ 2.5MG BASE	A078131	001	Sep 04, 2007	Feb DISC
>A>		@	EQ 2.5MG BASE	A078131	001	Sep 04, 2007	Feb DISC
>D>	AB		EQ 5MG BASE	A078131	002	Sep 04, 2007	Feb DISC
>A>		@	EQ 5MG BASE	A078131	002	Sep 04, 2007	Feb DISC
>D>	AB		EQ 10MG BASE	A078131	003	Sep 04, 2007	Feb DISC
>A>		@	EQ 10MG BASE	A078131	003	Sep 04, 2007	Feb DISC

AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM

TABLET;ORAL
AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM

>A>	AB	DR REDDYS LABS LTD	EQ 2.5MG BASE;EQ 10MG BASE	A203874	001	Mar 07, 2014	Feb NEWA
>A>	AB		EQ 2.5MG BASE;EQ 20MG BASE	A203874	002	Mar 07, 2014	Feb NEWA
>A>	AB		EQ 2.5MG BASE;EQ 40MG BASE	A203874	003	Mar 07, 2014	Feb NEWA
>A>	AB		EQ 5MG BASE;EQ 10MG BASE	A203874	004	Mar 07, 2014	Feb NEWA
>A>	AB		EQ 5MG BASE;EQ 20MG BASE	A203874	005	Mar 07, 2014	Feb NEWA
>A>	AB		EQ 5MG BASE;EQ 40MG BASE	A203874	006	Mar 07, 2014	Feb NEWA
>A>	AB		EQ 5MG BASE;EQ 80MG BASE	A203874	007	Mar 07, 2014	Feb NEWA
>A>	AB		EQ 10MG BASE;EQ 10MG BASE	A203874	008	Mar 07, 2014	Feb NEWA
>A>	AB		EQ 10MG BASE;EQ 20MG BASE	A203874	009	Mar 07, 2014	Feb NEWA
>A>	AB		EQ 10MG BASE;EQ 40MG BASE	A203874	010	Mar 07, 2014	Feb NEWA
>A>	AB		EQ 10MG BASE;EQ 80MG BASE	A203874	011	Mar 07, 2014	Feb NEWA

AMMONIA N-13

INJECTABLE;INTRAVENOUS
AMMONIA N 13

	AP	WA UNIV SCH MED	30mCi-300mCi/8ML (3.75-37.5mCi/ML)	A204506	001	Feb 07, 2014	Jan NEWA

AMOXICILLIN; CLARITHROMYCIN; LANSOPRAZOLE

CAPSULE, CAPSULE, DELAYED REL PELLETS, TABLET;ORAL

LANSOPRAZOLE, AMOXICILLIN AND CLARITHROMYCIN

>A>	AB	SANDOZ	500MG,N/A,N/A;N/A,500MG,N/A;N/A,N/A,30MG	A202588	001	Mar 04, 2014	Feb	NEWA

AMPICILLIN SODIUM

INJECTABLE;INJECTION

AMPICILLIN SODIUM

>D>	AP	IBI	EQ 1GM BASE/VIAL	A062719	002	May 12, 1987	Feb	CAHN
>D>	AP		EQ 2GM BASE/VIAL	A062797	002	Jul 12, 1993	Feb	CAHN
>D>	AP		EQ 125MG BASE/VIAL	A062797	001	Jul 12, 1993	Feb	CAHN
>D>	AP		EQ 250MG BASE/VIAL	A062719	001	May 12, 1987	Feb	CAHN
>D>	AP		EQ 500MG BASE/VIAL	A062719	003	May 12, 1987	Feb	CAHN
>A>	AP	ISTITUTO BIO ITA SPA	EQ 1GM BASE/VIAL	A062719	002	May 12, 1987	Feb	CAHN
>A>	AP		EQ 2GM BASE/VIAL	A062797	002	Jul 12, 1993	Feb	CAHN
	AP		EQ 10GM BASE/VIAL	A201404	001	Dec 20, 2013	Jan	CPOT
>A>	AP		EQ 125MG BASE/VIAL	A062797	001	Jul 12, 1993	Feb	CAHN
>A>	AP		EQ 250MG BASE/VIAL	A062719	001	May 12, 1987	Feb	CAHN
>A>	AP		EQ 500MG BASE/VIAL	A062719	003	May 12, 1987	Feb	CAHN

AMPICILLIN SODIUM; SULBACTAM SODIUM

INJECTABLE;INJECTION

AMPICILLIN AND SULBACTAM

>D>	AP	IBI	EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A065222	001	Nov 29, 2005	Feb	CAHN
>D>	AP		EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A065222	002	Nov 29, 2005	Feb	CAHN
>D>	AP		EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL	A065314	001	Nov 27, 2006	Feb	CAHN
>A>	AP	ISTITUTO BIO ITA SPA	EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A065222	001	Nov 29, 2005	Feb	CAHN
>A>	AP		EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A065222	002	Nov 29, 2005	Feb	CAHN
>A>	AP		EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL	A065314	001	Nov 27, 2006	Feb	CAHN

ASENAPINE MALEATE

TABLET;SUBLINGUAL

SAPHRIS

>A>		FOREST LABS INC	EQ 5MG BASE	N022117	001	Aug 13, 2009	Feb	CAHN
>A>	+		EQ 10MG BASE	N022117	002	Aug 13, 2009	Feb	CAHN
>D>		ORGANON SUB MERCK	EQ 5MG BASE	N022117	001	Aug 13, 2009	Feb	CAHN
>D>	+		EQ 10MG BASE	N022117	002	Aug 13, 2009	Feb	CAHN

AZILSARTAN KAMEDOXOMIL

TABLET;ORAL

EDARBI

>A>		ARBOR PHARMS IRELAND	EQ 40MG MEDOXOMIL	N200796	001	Feb 25, 2011	Feb	CAHN
>A>	+		EQ 80MG MEDOXOMIL	N200796	002	Feb 25, 2011	Feb	CAHN
>D>		ARBOR PHARMS LLC	EQ 40MG MEDOXOMIL	N200796	001	Feb 25, 2011	Feb	CAHN
>D>	+		EQ 80MG MEDOXOMIL	N200796	002	Feb 25, 2011	Feb	CAHN

AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE

TABLET;ORAL

EDARBYCLOR

>A>		ARBOR PHARMS IRELAND	EQ 40MG MEDOXOMIL;12.5MG	N202331	001	Dec 20, 2011	Feb	CAHN
>A>	+		EQ 40MG MEDOXOMIL;25MG	N202331	002	Dec 20, 2011	Feb	CAHN
>D>		ARBOR PHARMS LLC	EQ 40MG MEDOXOMIL;12.5MG	N202331	001	Dec 20, 2011	Feb	CAHN
>D>	+		EQ 40MG MEDOXOMIL;25MG	N202331	002	Dec 20, 2011	Feb	CAHN

BACITRACIN

OINTMENT;OPHTHALMIC

BACITRACIN

>D>	AT +	PERRIGO CO TENNESSEE	500 UNITS/GM	A061212	001		Feb	CTEC
>A>	+		500 UNITS/GM	A061212	001		Feb	CTEC

BENDROFLUMETHIAZIDE; NADOLOL

TABLET;ORAL

NADOLOL AND BENDROFLUMETHIAZIDE

	AB	MYLAN	5MG;40MG	A078688	001	Feb 15, 2008	Jan	CTNA
	AB		5MG;80MG	A078688	002	Feb 15, 2008	Jan	CTNA

BETAMETHASONE DIPROPIONATE; CLOTRIMAZOLE

LOTION;TOPICAL

LOTRISONE

AB	+	MERCK SHARP DOHME	EQ 0.05% BASE;1%	N020010	001	Dec 08, 2000	Jan	CAHN

BROMFENAC SODIUM

SOLUTION/DROPS;OPHTHALMIC

BROMDAY

AT	+	ISTA PHARMS INC	EQ 0.09% ACID	N021664	002	Oct 16, 2010	Jan	CFTG

BROMFENAC SODIUM

AT1		COASTAL PHARMS	EQ 0.09% ACID	A201211	001	May 11, 2011	Jan	CTEC
AT		HI-TECH PHARMACAL	EQ 0.09% ACID	A203395	001	Jan 22, 2014	Jan	NEWA
AT1		LUITPOLD	EQ 0.09% ACID	A202030	001	Jan 09, 2013	Jan	CTEC

BUDESONIDE

TABLET, EXTENDED RELEASE;ORAL

UCERIS

>A>	+	SALIX PHARMS INC	9MG	N203634	001	Jan 14, 2013	Feb	CAHN
>D>	+	SANTARUS	9MG	N203634	001	Jan 14, 2013	Feb	CAHN

BUPROPION HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

BUPROPION HYDROCHLORIDE

>D> BX		WATSON LABS	300MG	A077715	002	Jun 13, 2007	Feb	DISC
>A>	@		300MG	A077715	002	Jun 13, 2007	Feb	DISC
AB3		ZYDUS PHARMS USA INC	300MG	A201567	001	Jan 17, 2014	Jan	NEWA

BUSPIRONE HYDROCHLORIDE

TABLET;ORAL

BUSPIRONE HYDROCHLORIDE

AB		ZYDUS PHARMS USA INC	5MG	A078888	001	Feb 07, 2014	Jan	NEWA
AB			10MG	A078888	002	Feb 07, 2014	Jan	NEWA
AB			15MG	A078888	003	Feb 07, 2014	Jan	NEWA
AB			30MG	A078888	004	Feb 07, 2014	Jan	NEWA

CAFFEINE CITRATE

SOLUTION;INTRAVENOUS

CAFFEINE CITRATE

>A> AP		EXELA PHARMA SCIENCE	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	A077233	001	Sep 21, 2006	Feb	CAHN
>D> AP		PADDOCK LLC	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	A077233	001	Sep 21, 2006	Feb	CAHN

SOLUTION;ORAL

CAFFEINE CITRATE

>A> AA		EXELA PHARMA SCS LLC	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	A077304	001	Sep 21, 2006	Feb	CAHN
>D> AA		PADDOCK LLC	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	A077304	001	Sep 21, 2006	Feb	CAHN

CALCITRIOL

INJECTABLE;INJECTION

CALCITRIOL

>D> AP		TEVA PARENTERAL	0.002MG/ML	A075823	002	Mar 31, 2003	Feb	DISC
>A>	@		0.002MG/ML	A075823	002	Mar 31, 2003	Feb	DISC

CARBIDOPA

TABLET;ORAL

>A> CARBIDOPA

>A> AB		AMERIGEN PHARMS LTD	25MG	A203261	001	Mar 10, 2014	Feb	NEWA

LODOSYN

>D>	+	ATON	25MG	N017830	001		Feb	CFTG
>A> AB	+		25MG	N017830	001		Feb	CFTG

CARBINOXAMINE MALEATE

SOLUTION;ORAL

CARBINOXAMINE MALEATE

>D> AA		BOCA PHARMA LLC	4MG/5ML	A040814	001	Feb 26, 2008	Feb	CAHN
>A> AA		VINTAGE PHARMS	4MG/5ML	A040814	001	Feb 26, 2008	Feb	CAHN

TABLET;ORAL

CARBINOXAMINE MALEATE

>D> AA		BOCA PHARMA LLC	4MG	A040639	002	May 30, 2008	Feb	CAHN
>A> AA		VINTAGE PHARMS	4MG	A040639	002	May 30, 2008	Feb	CAHN

CARBOPLATIN

INJECTABLE;IV (INFUSION)

CARBOPLATIN

>D>	AP	+	PHARMACHEMIE	50MG/5ML (10MG/ML)	A077269	001	Oct 14, 2004	Feb	CAHN
>D>	AP	+		150MG/15ML (10MG/ML)	A077269	002	Oct 14, 2004	Feb	CAHN
>D>	AP	+		450MG/45ML (10MG/ML)	A077269	003	Oct 14, 2004	Feb	CAHN
>D>	AP	+		600MG/60ML (10MG/ML)	A077269	004	Dec 28, 2007	Feb	CAHN
>A>	AP	+	PHARMACHEMIE BV	50MG/5ML (10MG/ML)	A077269	001	Oct 14, 2004	Feb	CAHN
>A>	AP	+		150MG/15ML (10MG/ML)	A077269	002	Oct 14, 2004	Feb	CAHN
>A>	AP	+		450MG/45ML (10MG/ML)	A077269	003	Oct 14, 2004	Feb	CAHN
>A>	AP	+		600MG/60ML (10MG/ML)	A077269	004	Dec 28, 2007	Feb	CAHN

CARISOPRODOL

TABLET;ORAL

CARISOPRODOL

	AA		SCIEGEN PHARMS INC	350MG	A203374	001	Jan 27, 2014	Jan	NEWA

CEFACLOR

FOR SUSPENSION;ORAL

CEFACLOR

	AB	+	YUNG SHIN PHARM	EQ 375MG BASE/5ML	A065412	004	Feb 17, 2012	Jan	CRLD

CEFADROXIL/CEFADROXIL HEMIHYDRATE

FOR SUSPENSION;ORAL

CEFADROXIL

		@	ANI PHARMS INC	EQ 125MG BASE/5ML	A062698	001	Mar 01, 1989	Jan	CAHN
		@		EQ 250MG BASE/5ML	A062698	002	Mar 01, 1989	Jan	CAHN
		@		EQ 250MG BASE/5ML	A065278	001	Jan 20, 2006	Jan	CAHN
		@		EQ 500MG BASE/5ML	A062698	003	Mar 01, 1989	Jan	CAHN
		@		EQ 500MG BASE/5ML	A065278	002	Jan 20, 2006	Jan	CAHN

CEFTRIAXONE SODIUM

INJECTABLE;INJECTION

CEFTRIAXONE

>A>	AP		AGILA SPECLTS	EQ 10GM BASE/VIAL	A091068	001	Jan 07, 2013	Feb	CAHN
>D>	AP		STRIDES ARCOLAB LTD	EQ 10GM BASE/VIAL	A091068	001	Jan 07, 2013	Feb	CAHN

CHLORPROPAMIDE

TABLET;ORAL

CHLORPROPAMIDE

		@	ANI PHARMS INC	100MG	A088768	001	Oct 11, 1984	Jan	CAHN
		@		100MG	A088812	001	Oct 19, 1984	Jan	CAHN
>A>		@		100MG	A088840	001	Oct 25, 1984	Feb	CAHN
		@		100MG	A088918	001	Oct 16, 1984	Jan	CAHN
	AB			100MG	A088921	001	Apr 12, 1985	Jan	CAHN
		@		100MG	A089446	001	Nov 17, 1986	Jan	CAHN
		@		250MG	A088813	001	Oct 19, 1984	Jan	CAHN
		@		250MG	A088919	001	Oct 16, 1984	Jan	CAHN
	AB			250MG	A088922	001	Apr 12, 1985	Jan	CAHN
		@		250MG	A089447	001	Nov 17, 1986	Jan	CAHN
>D>		@	IVAX PHARMS	100MG	A088840	001	Oct 25, 1984	Feb	CAHN

GLUCAMIDE

		@	ANI PHARMS INC	250MG	A088641	001	Oct 11, 1984	Jan	CAHN

CICLOPIROX

CREAM;TOPICAL

CICLOPIROX

>D>	AB		TARO	0.77%	A076790	001	Apr 12, 2005	Feb	DISC
>A>		@		0.77%	A076790	001	Apr 12, 2005	Feb	DISC

CIMETIDINE HYDROCHLORIDE

SOLUTION;ORAL

CIMETIDINE HYDROCHLORIDE

	AA		ANI PHARMS INC	EQ 300MG BASE/5ML	A074610	001	Sep 26, 1996	Jan	CAHN
>A>		@		EQ 300MG BASE/5ML	A074859	001	Jul 09, 1998	Feb	CAHN
		@		EQ 300MG BASE/5ML	A075110	001	Jun 18, 1998	Jan	CAHN
>D>		@	TEVA PHARMS	EQ 300MG BASE/5ML	A074859	001	Jul 09, 1998	Feb	CAHN

CIPROFLOXACIN
FOR SUSPENSION;ORAL
CIPRO

>D>		BAYER HLTHCARE	250MG/5ML	N020780	001	Sep 26, 1997	Feb	CFTG
>A>	AB		250MG/5ML	N020780	001	Sep 26, 1997	Feb	CFTG
>D>	+		500MG/5ML	N020780	002	Sep 26, 1997	Feb	CFTG
>A>	AB +		500MG/5ML	N020780	002	Sep 26, 1997	Feb	CFTG

CIPROFLOXACIN

>A>	AB	LUPIN LTD	250MG/5ML	A200563	001	Mar 05, 2014	Feb	NEWA
>A>	AB		500MG/5ML	A200563	002	Mar 05, 2014	Feb	NEWA

CISPLATIN
INJECTABLE;INJECTION
CISPLATIN

>D>	AP	PHARMACHEMIE	1MG/ML	A074656	001	May 16, 2000	Feb	CAHN
>A>	AP	PHARMACHEMIE BV	1MG/ML	A074656	001	May 16, 2000	Feb	CAHN

CLINDAMYCIN PALMITATE HYDROCHLORIDE
FOR SOLUTION;ORAL
CLINDAMYCIN PALMITATE HYDROCHLORIDE

>A>	AA	AMNEAL PHARMS	EQ 75MG BASE/5ML	A203513	001	Mar 13, 2014	Feb	NEWA

CLINDAMYCIN PHOSPHATE
SOLUTION;TOPICAL
CLINDAMYCIN PHOSPHATE

>D>		@ BOCA PHARMA LLC	EQ 1% BASE	A062930	001	Jun 28, 1989	Feb	CAHN
>A>		@ VINTAGE PHARMS	EQ 1% BASE	A062930	001	Jun 28, 1989	Feb	CAHN

CLONIDINE HYDROCHLORIDE
INJECTABLE;INJECTION
CLONIDINE HYDROCHLORIDE

>A>	AP	ZYDUS PHARMS USA INC	1MG/10ML (0.1MG/ML)	A202601	001	Feb 20, 2014	Feb	NEWA
>A>	AP		5MG/10ML (0.5MG/ML)	A202601	002	Feb 20, 2014	Feb	NEWA

CLOPIDOGREL BISULFATE
TABLET;ORAL
CLOPIDOGREL BISULFATE

>A>	AB	APOTEX INC	EQ 300MG BASE	A076274	002	Mar 04, 2014	Feb	NEWA
	AB	MACLEODS PHARMS LTD	EQ 75MG BASE	A202928	001	Feb 10, 2014	Jan	NEWA

COLISTIMETHATE SODIUM
INJECTABLE;INJECTION
COLISTIMETHATE SODIUM

>A>	AP	SAGENT PHARMS	EQ 150MG BASE/VIAL	A201365	001	Feb 19, 2014	Feb	NEWA

CONIVAPTAN HYDROCHLORIDE
INJECTABLE;IV (INFUSION)
VAPRISOL

>D>		@ ASTELLAS	20MG/4ML (5MG/ML)	N021697	001	Dec 29, 2005	Feb	CAHN
>A>		@ CUMBERLAND PHARMS	20MG/4ML (5MG/ML)	N021697	001	Dec 29, 2005	Feb	CAHN

VAPRISOL IN 5% DEXTROSE IN PLASTIC CONTAINER

>D>	+	ASTELLAS	20MG/100ML (0.2MG/ML)	N021697	002	Oct 08, 2008	Feb	CAHN
>A>	+	CUMBERLAND PHARMS	20MG/100ML (0.2MG/ML)	N021697	002	Oct 08, 2008	Feb	CAHN

DAPAGLIFLOZIN
TABLET;ORAL
FARXIGA

>A>		ASTRAZENECA AB	5MG	N202293	001	Jan 08, 2014	Feb	CAHN
>A>	+		10MG	N202293	002	Jan 08, 2014	Feb	CAHN
>D>		BRISTOL MYERS SQUIBB	5MG	N202293	001	Jan 08, 2014	Feb	CAHN
			5MG	N202293	001	Jan 08, 2014	Jan	NEWA
>D>	+		10MG	N202293	002	Jan 08, 2014	Feb	CAHN
	+		10MG	N202293	002	Jan 08, 2014	Jan	NEWA

DECITABINE
POWDER;INTRAVENOUS
DECITABINE

	+	SUN PHARMA GLOBAL	50MG/VIAL	N205582	001	Jan 28, 2014	Jan	NEWA

DESIPRAMINE HYDROCHLORIDE

TABLET;ORAL

DESIPRAMINE HYDROCHLORIDE

		@	ANI PHARMS INC	25MG	A071800	001	Dec 08, 1987	Jan CAHN
		@		50MG	A071801	001	Dec 08, 1987	Jan CAHN
		@		75MG	A071802	001	Dec 08, 1987	Jan CAHN
>A>		@		100MG	A071803	001	May 29, 1997	Feb CAHN
>A>		@		150MG	A071804	001	May 29, 1997	Feb CAHN
>D>		@	BARR LABS INC	150MG	A071804	001	May 29, 1997	Feb CAHN
>D>		@	PLIVA	100MG	A071803	001	May 29, 1997	Feb CAHN

DESMOPRESSIN ACETATE

SPRAY, METERED;NASAL

DESMOPRESSIN ACETATE (NEEDS NO REFRIGERATION)

	AB		SUN PHARMA GLOBAL	0.01MG/SPRAY	A078271	001	Dec 23, 2013	Jan CMS2

DESVENLAFAXINE

TABLET, EXTENDED RELEASE;ORAL

DESVENLAFAXINE

>D>	BC		SUN PHARMA GLOBAL	50MG	N205583	001	Jan 28, 2014	Feb CTEC
	BC			50MG	N205583	001	Jan 28, 2014	Jan NEWA
>D>	BC	+		100MG	N205583	002	Jan 28, 2014	Feb CTEC
	BC	+		100MG	N205583	002	Jan 28, 2014	Jan NEWA

DESVENLAFAXINE FUMARATE

TABLET, EXTENDED RELEASE;ORAL

DESVENLAFAXINE FUMARATE

>A>		+	SUN PHARMA GLOBAL	EQ 50MG BASE	N205583	001	Jan 28, 2014	Feb CTEC
>A>		+		EQ 100MG BASE	N205583	002	Jan 28, 2014	Feb CTEC

DEXCHLORPHENIRAMINE MALEATE

TABLET;ORAL

DEXCHLORPHENIRAMINE MALEATE

		@	ANI PHARMS INC	2MG	A088682	001	Jan 17, 1986	Jan CAHN

DEXTROAMPHETAMINE SULFATE

TABLET;ORAL

DEXTROAMPHETAMINE SULFATE

>A>	AA		COREPHARMA	5MG	A090652	001	Mar 07, 2014	Feb NEWA
>A>	AA			10MG	A090652	002	Mar 07, 2014	Feb NEWA

DICLOFENAC POTASSIUM

FOR SOLUTION;ORAL

CAMBIA

		+	DEPOMED INC	50MG	N022165	001	Jun 17, 2009	Jan CAHN

DICLOFENAC SODIUM

SOLUTION;TOPICAL

PENNSAID

		+	MALLINCKRODT INC	2%	N204623	001	Jan 16, 2014	Jan NEWA

DIGOXIN

TABLET;ORAL

LANOXIN

			COVIS PHARMA	0.0625MG	N020405	001	Sep 30, 1997	Jan CMFD
				0.1875MG	N020405	003	Sep 30, 1997	Jan CMFD

DILTIAZEM HYDROCHLORIDE

INJECTABLE;INJECTION

DILTIAZEM HYDROCHLORIDE

>A>		@	AGILA SPECLTS	5MG/ML	A075375	001	Sep 30, 1999	Feb CAHN
>D>		@	APOTEX INC	5MG/ML	A075375	001	Sep 30, 1999	Feb CAHN

DISULFIRAM

TABLET;ORAL

DISULFIRAM

	AB		ROXANE	250MG	A202652	001	Feb 05, 2014	Jan NEWA
	AB			500MG	A202652	002	Feb 05, 2014	Jan NEWA

DONEPEZIL HYDROCHLORIDE

TABLET;ORAL

DONEPEZIL HYDROCHLORIDE

	AB		MACLEODS PHARMS LTD	23MG	A202631	001	Jan 22, 2014	Jan NEWA

DOXERCALCIFEROL

INJECTABLE;INJECTION

DOXERCALCIFEROL

	AP		SANDOZ	4MCG/2ML (2MCG/ML)	A200926	001	Feb 04, 2014	Jan NEWA

DOXORUBICIN HYDROCHLORIDE

INJECTABLE;INJECTION

DOXORUBICIN HYDROCHLORIDE

>D>	AP		PHARMACHEMIE	2MG/ML	A063336	001	Feb 28, 1995	Feb CAHN
>D>	AP			10MG/VIAL	A063097	001	May 21, 1990	Feb CAHN
>D>	AP			20MG/VIAL	A063097	002	May 21, 1990	Feb CAHN
>D>	AP			50MG/VIAL	A063097	003	May 21, 1990	Feb CAHN
>D>	AP			200MG/100ML	A063336	004	Feb 28, 1995	Feb CAHN
>A>	AP		PHARMACHEMIE BV	2MG/ML	A063336	001	Feb 28, 1995	Feb CAHN
>A>	AP			10MG/VIAL	A063097	001	May 21, 1990	Feb CAHN
>A>	AP			20MG/VIAL	A063097	002	May 21, 1990	Feb CAHN
>A>	AP			50MG/VIAL	A063097	003	May 21, 1990	Feb CAHN
>A>	AP			200MG/100ML	A063336	004	Feb 28, 1995	Feb CAHN

DOXYCYCLINE

CAPSULE;ORAL

DOXYCYCLINE

>A>	AB		LUPIN LTD	EQ 50MG BASE	A204234	001	Mar 05, 2014	Feb NEWA
>A>	AB			EQ 75MG BASE	A204234	002	Mar 05, 2014	Feb NEWA
>A>	AB			EQ 100MG BASE	A204234	003	Mar 05, 2014	Feb NEWA

DOXYCYCLINE HYCLATE

TABLET, DELAYED RELEASE;ORAL

DORYX

>D>	AB	+	MAYNE PHARMA	EQ 150MG BASE	N050795	003	Jun 20, 2008	Feb CRLD
>A>	AB			EQ 150MG BASE	N050795	003	Jun 20, 2008	Feb CRLD
>D>				EQ 200MG BASE	N050795	005	Apr 11, 2013	Feb CRLD
>A>		+		EQ 200MG BASE	N050795	005	Apr 11, 2013	Feb CRLD

>A> DROXIDOPA

>A> CAPSULE;ORAL

>A> NORTHERA

>A>			CHELSEA THERAPS INC	100MG	N203202	001	Feb 18, 2014	Feb NEWA
>A>				200MG	N203202	002	Feb 18, 2014	Feb NEWA
>A>		+		300MG	N203202	003	Feb 18, 2014	Feb NEWA

DUTASTERIDE; TAMSULOSIN HYDROCHLORIDE

CAPSULE;ORAL

>A> DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE

>A>	AB		ANCHEN PHARMS	0.5MG;0.4MG	A202509	001	Feb 26, 2014	Feb NEWA

JALYN

>D>		+	GLAXOSMITHKLINE	0.5MG;0.4MG	N022460	001	Jun 14, 2010	Feb CFTG
>A>	AB	+		0.5MG;0.4MG	N022460	001	Jun 14, 2010	Feb CFTG

ECONAZOLE NITRATE

AEROSOL, FOAM;TOPICAL

ECOZA

>D>		+	AMDERMA PHARMS	1%	N205175	001	Oct 24, 2013	Feb CAHN
>A>		+	VELDANA MEDICAL SA	1%	N205175	001	Oct 24, 2013	Feb CAHN

CREAM;TOPICAL

SPECTAZOLE

			@ MERZ PHARMS LLC	1%	N018751	001	Dec 23, 1982	Jan CAHN

ERYTHROMYCIN STEARATE

TABLET;ORAL

ERYTHROMYCIN STEARATE

>A>			@ ANI PHARMS INC	EQ 250MG BASE	A061461	001		Feb CAHN
			@	EQ 250MG BASE	A061591	001		Jan CAHN
>A>			@	EQ 500MG BASE	A061461	002		Feb CAHN
>A>			@	EQ 500MG BASE	A063179	001	May 15, 1990	Feb CAHN
>D>			@ BARR	EQ 500MG BASE	A063179	001	May 15, 1990	Feb CAHN

TABLET;ORAL
ERYTHROMYCIN STEARATE

>D>		@ IVAX SUB TEVA PHARMS	EQ 250MG BASE	A061461	001			Feb CAHN
>D>		@	EQ 500MG BASE	A061461	002			Feb CAHN

ESCITALOPRAM OXALATE

TABLET;ORAL
ESCITALOPRAM OXALATE

>D>	AB	IVAX SUB TEVA PHARMS	EQ 5MG BASE	A076765	001	Mar 14, 2012		Feb CAHN
>D>	AB		EQ 10MG BASE	A076765	002	Mar 14, 2012		Feb CAHN
>D>	AB		EQ 20MG BASE	A076765	003	Mar 14, 2012		Feb CAHN
>A>	AB	TEVA PHARMS USA	EQ 5MG BASE	A076765	001	Mar 14, 2012		Feb CAHN
>A>	AB		EQ 10MG BASE	A076765	002	Mar 14, 2012		Feb CAHN
>A>	AB		EQ 20MG BASE	A076765	003	Mar 14, 2012		Feb CAHN

ESZOPICLONE

TABLET;ORAL
ESZOPICLONE

	AB	TEVA	1MG	A091169	001	May 23, 2011		Jan CMFD
	AB		2MG	A091169	002	May 23, 2011		Jan CMFD
	AB		3MG	A091169	003	May 23, 2011		Jan CMFD

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET;ORAL-28
LEVONORGESTREL AND ETHINYL ESTRADIOL

	AB1	HAUPT PHARMA	0.02MG;0.1MG	A201108	001	Feb 05, 2014		Jan NEWA

ETODOLAC

CAPSULE;ORAL
ETODOLAC

>A>		@ ANI PHARMS INC	200MG	A074899	001	Jul 08, 1997		Feb CAHN
		@	200MG	A075126	001	Sep 16, 1999		Jan CAHN
>A>		@	300MG	A074899	002	Jul 08, 1997		Feb CAHN
	AB		300MG	A075126	002	Sep 16, 1999		Jan CAHN
>D>		@ IVAX SUB TEVA PHARMS	200MG	A074899	001	Jul 08, 1997		Feb CAHN
>D>		@	300MG	A074899	002	Jul 08, 1997		Feb CAHN

ETOMIDATE

INJECTABLE;INJECTION
ETOMIDATE

>A>	AP	AGILA SPECLTS	2MG/ML	A078289	001	Jan 02, 2009		Feb CAHN
>D>	AP	STRIDES ARCOLAB LTD	2MG/ML	A078289	001	Jan 02, 2009		Feb CAHN

ETOPOSIDE

INJECTABLE;INJECTION
ETOPOSIDE

>D>		@ PHARMACHEMIE	20MG/ML	A074227	001	Feb 22, 1996		Feb CAHN
>A>		@ PHARMACHEMIE BV	20MG/ML	A074227	001	Feb 22, 1996		Feb CAHN

FAMOTIDINE

INJECTABLE;INJECTION
FAMOTIDINE PRESERVATIVE FREE

>A>	AP	BEDFORD LABS	10MG/ML	A075825	001	Apr 17, 2001		Feb CAHN
>D>	AP	BEN VENUE	10MG/ML	A075825	001	Apr 17, 2001		Feb CAHN

FENOFIBRATE

TABLET;ORAL
FENOGLIDE

>D>		SALIX PHARMS INC	40MG	N022118	001	Aug 10, 2007		Feb CAHN
>D>	+		120MG	N022118	002	Aug 10, 2007		Feb CAHN
>A>		SANTARUS INC	40MG	N022118	001	Aug 10, 2007		Feb CAHN
>A>	+		120MG	N022118	002	Aug 10, 2007		Feb CAHN

FLUDEOXYGLUCOSE F-18

INJECTABLE;INTRAVENOUS
FLUDEOXYGLUCOSE F18

	AP	ESSENTIAL ISOTOPES	20-300mCi/ML	A203946	001	Feb 05, 2014		Jan NEWA
	AP	LANTHEUS MEDICAL	20-200mCi/ML	A203664	001	Feb 04, 2014		Jan NEWA
>D>	+	WEILL MEDCL COLL	10-100mCi/ML	N021768	001	Aug 05, 2004		Feb DISC
>A>		@	10-100mCi/ML	N021768	001	Aug 05, 2004		Feb DISC
	AP	WUSM CYCLOTRON	20-300mCi/ML	A203935	001	Feb 05, 2014		Jan NEWA

FLUDROCORTISONE ACETATE

TABLET;ORAL

FLUDROCORTISONE ACETATE

AB		HIKMA PHARMS	0.1MG	A091302	001	Jul 22, 2011	Jan	CAHN
AB			0.1MG	A091302	001	Jul 22, 2011	Jan	CAHN
AB			0.1MG	A091302	001	Jul 22, 2011	Jan	CAHN
AB			0.1MG	A091302	001	Jul 22, 2011	Jan	CAHN

FLUOXETINE HYDROCHLORIDE

CAPSULE;ORAL

FLUOXETINE HYDROCHLORIDE

AB2		ANI PHARMS INC	EQ 10MG BASE	A076287	001	May 20, 2008	Jan	CAHN
AB2			EQ 20MG BASE	A076287	002	May 20, 2008	Jan	CAHN

TABLET;ORAL

SARAFEM

AB1		WARNER CHILCOTT LLC	EQ 10MG BASE	N021860	001	May 19, 2006	Jan	CFTG
AB1			EQ 15MG BASE	N021860	002	May 19, 2006	Jan	CFTG
AB1	+		EQ 20MG BASE	N021860	003	May 19, 2006	Jan	CFTG

SELFEMRA

AB1		TEVA PHARMS USA	EQ 10MG BASE	A200151	001	Feb 03, 2014	Jan	NEWA
AB1			EQ 15MG BASE	A200151	002	Feb 03, 2014	Jan	NEWA
AB1			EQ 20MG BASE	A200151	003	Feb 03, 2014	Jan	NEWA

FLUPHENAZINE HYDROCHLORIDE

ELIXIR;ORAL

FLUPHENAZINE HYDROCHLORIDE

>A>		@ ANI PHARMS INC	2.5MG/5ML	A081310	001	Apr 29, 1993	Feb	CAHN
>D>		@ TEVA PHARMS	2.5MG/5ML	A081310	001	Apr 29, 1993	Feb	CAHN

FOLIC ACID

TABLET;ORAL

FOLIC ACID

AA		CADILA PHARMS LTD	1 MG	A202437	001	Jan 27, 2014	Jan	NEWA

FOSINOPRIL SODIUM; HYDROCHLOROTHIAZIDE

TABLET;ORAL

FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE

>A>	AB	EMCURE PHARMS INDIA	10MG;12.5MG	A079025	001	Sep 17, 2010	Feb	CAIN
>A>	AB +		20MG;12.5MG	A079025	002	Sep 17, 2010	Feb	CAIN

FOSINOPRIL; HYDROCHLOROTHIAZIDE

TABLET;ORAL

FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE

>D>	AB	EMCURE PHARMS INDIA	10MG;12.5MG	A079025	001	Sep 17, 2010	Feb	CAIN
>D>	AB +		20MG;12.5MG	A079025	002	Sep 17, 2010	Feb	CAIN
	AB +		20MG;12.5MG	A079025	002	Sep 17, 2010	Jan	CRLD

FOSPHENYTOIN SODIUM

INJECTABLE;INJECTION

CEREBYX

>D>		@ PARKE DAVIS	EQ 50MG PHENYTOIN NA/ML	N020450	001	Aug 05, 1996	Feb	CMFD
>A>	AP		EQ 50MG PHENYTOIN NA/ML	N020450	001	Aug 05, 1996	Feb	CMFD

FOSPHENYTOIN SODIUM

>A>	AP	AGILA SPECLTS	EQ 50MG PHENYTOIN NA/ML	A078736	001	Jun 08, 2010	Feb	CAHN
>D>	AP	STRIDES ARCOLAB	EQ 50MG PHENYTOIN NA/ML	A078736	001	Jun 08, 2010	Feb	CAHN

FUROSEMIDE

INJECTABLE;INJECTION

FUROSEMIDE

AP		CLARIS LIFESCIENCES	10MG/ML	A202747	001	Jan 27, 2014	Jan	NEWA

GABAPENTIN

TABLET;ORAL

GABAPENTIN

>A>	AB	ACI HEALTHCARE LTD	600MG	A203244	002	Jul 12, 2013	Feb	CAHN
>A>	AB		800MG	A203244	001	Jul 12, 2013	Feb	CAHN
>D>	AB	ALLIED PHARMA INC	600MG	A203244	002	Jul 12, 2013	Feb	CAHN
>D>	AB		800MG	A203244	001	Jul 12, 2013	Feb	CAHN

GLATIRAMER ACETATE

INJECTABLE;SUBCUTANEOUS

COPAXONE

	+	TEVA PHARMS USA	40MG/ML	N020622	003	Jan 28, 2014	Jan NEWA

GLYCOPYRROLATE

TABLET;ORAL

GLYCOPYRROLATE

>D>	AA	BOCA PHARMA LLC	1MG	A090020	001	Oct 19, 2011	Feb CAHN
>D>	AA		2MG	A090020	002	Oct 19, 2011	Feb CAHN
	AA	STASON PHARMS	1MG	A091182	001	Feb 03, 2014	Jan NEWA
	AA		2MG	A091182	002	Feb 03, 2014	Jan NEWA
>A>	AA	VINTAGE PHARMS	1MG	A090020	001	Oct 19, 2011	Feb CAHN
>A>	AA		2MG	A090020	002	Oct 19, 2011	Feb CAHN

GUANABENZ ACETATE

TABLET;ORAL

GUANABENZ ACETATE

		ANI PHARMS INC	EQ 4MG BASE	A074149	001	Apr 07, 1995	Jan CAHN
	+		EQ 8MG BASE	A074149	002	Apr 07, 1995	Jan CAHN

HALOPERIDOL DECANOATE

INJECTABLE;INJECTION

HALOPERIDOL DECANOATE

>D>		@ AGILA SPECLTS	EQ 50MG BASE/ML	A075440	001	Feb 28, 2000	Feb CMFD
>A>	AO		EQ 50MG BASE/ML	A075440	001	Feb 28, 2000	Feb CMFD
>D>		@	EQ 100MG BASE/ML	A075440	002	Feb 28, 2000	Feb CMFD
>A>	AO		EQ 100MG BASE/ML	A075440	002	Feb 28, 2000	Feb CMFD

HYDROCHLOROTHIAZIDE; MOEXIPRIL HYDROCHLORIDE

TABLET;ORAL

MOEXIPRIL HYDROCHLORIDE AND HYDROCHOLROTHIAZIDE

>A>	AB	INDICUS PHARMA	12.5MG;7.5MG	A202150	001	Mar 07, 2014	Feb NEWA
>A>	AB		12.5MG;15MG	A202150	002	Mar 07, 2014	Feb NEWA
>A>	AB		25MG;15MG	A202150	003	Mar 07, 2014	Feb NEWA

HYDROCHLOROTHIAZIDE; TELMISARTAN

TABLET;ORAL

MICARDIS HCT

>D>		BOEHRINGER INGELHEIM	12.5MG;40MG	N021162	001	Nov 17, 2000	Feb CFTG
>A>	AB		12.5MG;40MG	N021162	001	Nov 17, 2000	Feb CFTG
>D>			12.5MG;80MG	N021162	002	Nov 17, 2000	Feb CFTG
>A>	AB		12.5MG;80MG	N021162	002	Nov 17, 2000	Feb CFTG
>D>		+	25MG;80MG	N021162	003	Apr 19, 2004	Feb CFTG
>A>	AB	+	25MG;80MG	N021162	003	Apr 19, 2004	Feb CFTG

TELMISARTAN AND HYDROCHLOROTHIAZIDE

>A>	AB	ALEMBIC PHARMS LTD	12.5MG;40MG	A203010	001	Feb 25, 2014	Feb NEWA
>A>	AB		12.5MG;80MG	A203010	002	Feb 25, 2014	Feb NEWA
>A>	AB		25MG;80MG	A203010	003	Feb 25, 2014	Feb NEWA
>A>	AB	MYLAN PHARMS INC	12.5MG;40MG	A091648	001	Feb 25, 2014	Feb NEWA
>A>	AB		12.5MG;80MG	A091648	002	Feb 25, 2014	Feb NEWA
>A>	AB		25MG;80MG	A091648	003	Feb 25, 2014	Feb NEWA
>A>	AB	TORRENT PHARMS LTD	12.5MG;40MG	A201192	001	Feb 25, 2014	Feb NEWA
>A>	AB		12.5MG;80MG	A201192	002	Feb 25, 2014	Feb NEWA
>A>	AB		25MG;80MG	A201192	003	Feb 25, 2014	Feb NEWA

HYDROCORTISONE ACETATE; PRAMOXINE HYDROCHLORIDE

AEROSOL, METERED;TOPICAL

HYDROCORTISONE ACETATE 1% AND PRAMOXINE HYDROCHLORIDE 1%

>D>		@ BOCA PHARMA LLC	1%;1%	A089440	001	May 17, 1988	Feb CAHN
>A>		@ VINTAGE PHARMS	1%;1%	A089440	001	May 17, 1988	Feb CAHN

IBANDRONATE SODIUM

INJECTABLE;INTRAVENOUS

BONIVA

>D>		+ ROCHE	EQ 3MG BASE/3ML	N021858	001	Jan 06, 2006	Feb CFTG
>A>	AP	+	EQ 3MG BASE/3ML	N021858	001	Jan 06, 2006	Feb CFTG

IBANDRONATE SODIUM

>A>	AP	SUN PHARM INDS LTD	EQ 3MG BASE/3ML	A090853	001	Feb 14, 2014	Feb NEWA

INDOMETHACIN

CAPSULE;ORAL

TIVORBEX

>A>			IROKO PHARMS LLC	20MG	N204768	001	Feb 24, 2014	Feb NEWA
>A>		+		40MG	N204768	002	Feb 24, 2014	Feb NEWA

INSULIN ASPART RECOMBINANT

INJECTABLE;SUBCUTANEOUS

NOVOLOG FLEXTOUCH

>A>		+	NOVO NORDISK INC	300 UNITS/3ML (100 UNITS/ML)	N020986	005	Oct 31, 2013	Feb NEWA

INSULIN DETEMIR RECOMBINANT

INJECTABLE;SUBCUTANEOUS

LEVEMIR FLEXTOUCH

>A>		+	NOVO NORDISK INC	300 UNITS/3ML (100 UNITS/ML)	N021536	005	Oct 31, 2013	Feb NEWA

ISOFLURANE

LIQUID;INHALATION

ISOFLURANE

>A>	AN		PIRAMAL ENT	99.9%	A074502	001	Jun 27, 1995	Feb CAHN
>D>	AN		RHODIA	99.9%	A074502	001	Jun 27, 1995	Feb CAHN

ISOSORBIDE MONONITRATE

TABLET;ORAL

ISOSORBIDE MONONITRATE

	AB		ANI PHARMS INC	20MG	A075147	001	Nov 27, 1998	Jan CAHN

ISRADIPINE

CAPSULE;ORAL

ISRADIPINE

>D>	AB		MIKAH PHARMA	2.5MG	A077169	001	Apr 24, 2006	Feb DISC
>A>		@		2.5MG	A077169	001	Apr 24, 2006	Feb DISC
>D>	AB			5MG	A077169	002	Apr 24, 2006	Feb DISC
>A>		@		5MG	A077169	002	Apr 24, 2006	Feb DISC
>D>	AB		WATSON LABS	2.5MG	A077317	001	Jan 05, 2006	Feb CTEC
>A>				2.5MG	A077317	001	Jan 05, 2006	Feb CTEC
>D>	AB	+		5MG	A077317	002	Jan 05, 2006	Feb CTEC
>A>		+		5MG	A077317	002	Jan 05, 2006	Feb CTEC

KETOROLAC TROMETHAMINE

SOLUTION/DROPS;OPHTHALMIC

ACUVAIL

	AT	+	ALLERGAN	0.45%	N022427	001	Jul 22, 2009	Jan CFTG

KETOROLAC TROMETHAMINE

>D>	AT		AKORN	0.45%	A203376	001	Feb 10, 2014	Feb DISC
>A>		@		0.45%	A203376	001	Feb 10, 2014	Feb DISC
	AT			0.45%	A203376	001	Feb 10, 2014	Jan NEWA

LAMIVUDINE; ZIDOVUDINE

TABLET;ORAL

LAMIVUDINE AND ZIDOVUDINE

	AB		HETERO LABS LTD V	150MG;300MG	A203259	001	Feb 03, 2014	Jan NEWA

LANSOPRAZOLE

TABLET, DELAYED RELEASE, ORALLY DISINTEGRATING;ORAL

LANSOPRAZOLE

		@	ANI PHARMS INC	15MG	A078730	001	Oct 15, 2010	Jan CAHN
		@		30MG	A078730	002	Oct 15, 2010	Jan CAHN

LEVETIRACETAM

TABLET;ORAL

LEVETIRACETAM

>D>	AB		BOCA PHARMA LLC	250MG	A077319	001	Mar 20, 2009	Feb CAHN
>D>	AB			500MG	A077319	002	Mar 20, 2009	Feb CAHN
>D>	AB			750MG	A077319	003	Mar 20, 2009	Feb CAHN
>A>	AB		VINTAGE PHARMS	250MG	A077319	001	Mar 20, 2009	Feb CAHN
>A>	AB			500MG	A077319	002	Mar 20, 2009	Feb CAHN
>A>	AB			750MG	A077319	003	Mar 20, 2009	Feb CAHN

TABLET, EXTENDED RELEASE;ORAL
LEVETIRACETAM

>D>	AB		BOCA PHARMA LLC	500MG	A201464	001	May 25, 2012	Feb CAHN
>D>	AB			750MG	A201464	002	May 25, 2012	Feb CAHN
>A>	AB		VINTAGE PHARMS	500MG	A201464	001	May 25, 2012	Feb CAHN
>A>	AB			750MG	A201464	002	May 25, 2012	Feb CAHN

LEVOCETIRIZINE DIHYDROCHLORIDE
SOLUTION;ORAL
LEVOCETIRIZINE DIHYDROCHLORIDE

	AA		L PERRIGO CO	2.5MG/5ML	A091263	001	Nov 07, 2011	Jan CAHN

LEVORPHANOL TARTRATE
TABLET;ORAL
LEVORPHANOL TARTRATE

>D>			ROXANE	2MG	A074278	001	Mar 31, 2000	Feb CRLD
>A>		+		2MG	A074278	001	Mar 31, 2000	Feb CRLD

LIDOCAINE HYDROCHLORIDE
JELLY;TOPICAL
ANESTACON

			@ DSM PHARMS INC	2%	A080429	001		Jan CAHN

SOLUTION;TOPICAL
LIDOCAINE HYDROCHLORIDE

>A>	AT		IGI LABS INC	4%	A204494	001	Mar 12, 2014	Feb NEWA

LOTEPREDNOL ETABONATE
GEL;OPHTHALMIC
LOTEMAX

>D>		+	BAUSCH AND LOMB	0.5%	N202872	001	Sep 28, 2012	Feb CAHN
>A>		+	BAUSCH AND LOMB INC	0.5%	N202872	001	Sep 28, 2012	Feb CAHN

LULICONAZOLE
CREAM;TOPICAL
LUZU

		+	MEDICIS	1%	N204153	001	Nov 14, 2013	Jan CRLD

METFORMIN HYDROCHLORIDE
TABLET, EXTENDED RELEASE;ORAL
GLUMETZA

>A>		+	SALIX PHARMS INC	1GM	N021748	002	Jun 03, 2005	Feb CTEC
>A>				500MG	N021748	001	Jun 03, 2005	Feb CTEC
>D>	AB3	+	SANTARUS	1GM	N021748	002	Jun 03, 2005	Feb CTEC
>D>	AB3			500MG	N021748	001	Jun 03, 2005	Feb CTEC

METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE
TABLET;ORAL
PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE

>A>	AB		TEVA PHARMS USA	500MG;EQ 15MG BASE	A091155	001	Mar 10, 2014	Feb NEWA
>A>	AB			850MG;EQ 15MG BASE	A091155	002	Mar 10, 2014	Feb NEWA

METHAZOLAMIDE
TABLET;ORAL
METHAZOLAMIDE

	AB		ANI PHARMS INC	25MG	A040001	001	Jun 30, 1993	Jan CAHN
	AB			50MG	A040001	002	Jun 30, 1993	Jan CAHN

METHIMAZOLE
TABLET;ORAL
METHIMAZOLE

>D>	AB		BOCA PHARMA LLC	5MG	A202068	001	Mar 07, 2012	Feb CAHN
>D>	AB			10MG	A202068	002	Mar 07, 2012	Feb CAHN
>A>	AB		VINTAGE PHARMS	5MG	A202068	001	Mar 07, 2012	Feb CAHN
>A>	AB			10MG	A202068	002	Mar 07, 2012	Feb CAHN

METHSCOPOLAMINE BROMIDE
TABLET;ORAL
METHSCOPOLAMINE BROMIDE

>D>	AA		BOCA PHARMA LLC	2.5MG	A040624	001	Dec 28, 2006	Feb CAHN
>D>	AA			5MG	A040624	002	Dec 28, 2006	Feb CAHN
>A>	AA		VINTAGE PHARMS	2.5MG	A040624	001	Dec 28, 2006	Feb CAHN
>A>	AA			5MG	A040624	002	Dec 28, 2006	Feb CAHN

METHYLERGONOVINE MALEATE

INJECTABLE;INJECTION

METHERGINE

>A>	AP	+	EDISON THERAPS LLC	0.2MG/ML	N006035	004			Feb CAHN
>D>	AP	+	US PHARMS HOLDINGS I	0.2MG/ML	N006035	004			Feb CAHN

TABLET;ORAL

METHERGINE

>A>	AB	+	EDISON THERAPS LLC	0.2MG	N006035	003			Feb CAHN
>D>	AB	+	US PHARMS HOLDINGS I	0.2MG	N006035	003			Feb CAHN

METHYLPHENIDATE HYDROCHLORIDE

TABLET;ORAL

METHYLPHENIDATE HYDROCHLORIDE

>A>	AB		COREPHARMA	5MG	A091159	001	Mar 12, 2014		Feb NEWA
>A>	AB			10MG	A091159	002	Mar 12, 2014		Feb NEWA
>A>	AB			20MG	A091159	003	Mar 12, 2014		Feb NEWA

METRONIDAZOLE

TABLET;ORAL

METRONIDAZOLE

	AB		UNICHEM LABS LTD	250MG	A203458	001	Jan 22, 2014		Jan NEWA
	AB			500MG	A203458	002	Jan 22, 2014		Jan NEWA

MIVACURIUM CHLORIDE

INJECTABLE;INJECTION

MIVACURIUM CHLORIDE

>A>		@	AGILA SPECLTS	EQ 2MG BASE/ML	A078562	001	Apr 30, 2009		Feb CAHN
>D>		@	STRIDES ARCOLAB LTD	EQ 2MG BASE/ML	A078562	001	Apr 30, 2009		Feb CAHN

MODAFINIL

TABLET;ORAL

MODAFINIL

	AB		APOTEX INC	100MG	A077667	001	Feb 03, 2014		Jan NEWA
	AB			200MG	A077667	002	Feb 03, 2014		Jan NEWA

MORPHINE SULFATE

SOLUTION;ORAL

MORPHINE SULFATE

	AA		CARACO	10MG/5ML	A201011	001	Feb 05, 2014		Jan NEWA
	AA			20MG/5ML	A201011	002	Feb 05, 2014		Jan NEWA

MOXIFLOXACIN HYDROCHLORIDE

TABLET;ORAL

AVELOX

>D>		+	BAYER HLTHCARE	EQ 400MG BASE	N021085	001	Dec 10, 1999		Feb CFTG
>A>	AB	+		EQ 400MG BASE	N021085	001	Dec 10, 1999		Feb CFTG

MOXIFLOXACIN HYDROCHLORIDE

>A>	AB		AUROBINDO PHARMA LTD	EQ 400MG BASE	A202632	001	Mar 04, 2014		Feb NEWA
>A>	AB		DR REDDYS LABS LTD	EQ 400MG BASE	A076938	001	Mar 04, 2014		Feb NEWA
>A>	AB		TEVA PHARMS USA	EQ 400MG BASE	A077437	001	Feb 18, 2014		Feb NEWA

NAFCILLIN SODIUM

INJECTABLE;INJECTION

NAFCILLIN SODIUM

	AP		ANTIBIOTICE	EQ 1GM BASE/VIAL	A090560	001	Oct 03, 2011		Jan CPOT
	AP			EQ 2GM BASE/VIAL	A090560	002	Oct 03, 2011		Jan CPOT
>D>	AP		IBI	EQ 1GM BASE/VIAL	A090002	001	Jun 30, 2011		Feb CAHN
>D>	AP			EQ 2GM BASE/VIAL	A090002	002	Jun 30, 2011		Feb CAHN
>D>	AP			EQ 10GM BASE/VIAL	A090005	001	Apr 20, 2011		Feb CAHN
>A>	AP		ISTITUTO BIO ITA SPA	EQ 1GM BASE/VIAL	A090002	001	Jun 30, 2011		Feb CAHN
>A>	AP			EQ 2GM BASE/VIAL	A090002	002	Jun 30, 2011		Feb CAHN
>A>	AP			EQ 10GM BASE/VIAL	A090005	001	Apr 20, 2011		Feb CAHN

NALOXONE HYDROCHLORIDE

INJECTABLE;INJECTION

NALOXONE HYDROCHLORIDE

>A>	AP		MYLAN INSTITUTIONAL	0.4MG/ML	A204997	001	Mar 06, 2014		Feb NEWA

NAPROXEN

TABLET;ORAL

NAPROXEN

>D>	AB		DAVA PHARMS INC	250MG	A074410	001	Apr 28, 1995	Feb DISC
>A>		@		250MG	A074410	001	Apr 28, 1995	Feb DISC
>D>	AB			375MG	A074410	002	Apr 28, 1995	Feb DISC
>A>		@		375MG	A074410	002	Apr 28, 1995	Feb DISC
>D>	AB			500MG	A074410	003	Apr 28, 1995	Feb DISC
>A>		@		500MG	A074410	003	Apr 28, 1995	Feb DISC

NARATRIPTAN HYDROCHLORIDE

TABLET;ORAL

NARATRIPTAN

	AB		APOTEX CORP	EQ 1MG BASE	A091373	001	Apr 22, 2011	Jan CAIN
	AB			EQ 2.5MG BASE	A091373	002	Apr 22, 2011	Jan CAIN
	AB		SUN PHARM INDS LTD	EQ 2.5MG BASE	A091552	001	Feb 14, 2011	Jan CAIN

NEVIRAPINE

TABLET;ORAL

NEVIRAPINE

	AB		STRIDES ARCOLAB LTD	200MG	A078195	001	May 22, 2012	Jan CAHN

NICARDIPINE HYDROCHLORIDE

CAPSULE;ORAL

NICARDIPINE HYDROCHLORIDE

	AB		ANI PHARMS INC	20MG	A074439	001	Dec 10, 1996	Jan CAHN
	AB			20MG	A074540	001	Oct 28, 1996	Jan CAHN
	AB			30MG	A074439	002	Dec 10, 1996	Jan CAHN
	AB			30MG	A074540	002	Oct 28, 1996	Jan CAHN

INJECTABLE;INJECTION

NICARDIPINE HYDROCHLORIDE

	AP		LUITPOLD	25MG/10ML (2.5MG/ML)	A090534	001	Nov 17, 2009	Jan CAHN

NIZATIDINE

CAPSULE;ORAL

NIZATIDINE

		@	ANI PHARMS INC	150MG	A075461	001	Jul 08, 2002	Jan CAHN
	AB			150MG	A075668	001	Sep 12, 2002	Jan CAHN
		@		300MG	A075461	002	Jul 08, 2002	Jan CAHN
	AB			300MG	A075668	002	Sep 12, 2002	Jan CAHN

OMEPRAZOLE; SODIUM BICARBONATE

CAPSULE;ORAL

ZEGERID

>D>	AB		SALIX PHARMS INC	20MG;1.1GM	N021849	001	Feb 27, 2006	Feb CAHN
>D>	AB	+		40MG;1.1GM	N021849	002	Feb 27, 2006	Feb CAHN
>A>	AB		SANTARUS INC	20MG;1.1GM	N021849	001	Feb 27, 2006	Feb CAHN
>A>	AB	+		40MG;1.1GM	N021849	002	Feb 27, 2006	Feb CAHN

FOR SUSPENSION;ORAL

ZEGERID

>D>	AB		SALIX PHARMS INC	20MG/PACKET;1.68GM/PACKET	N021636	001	Jun 15, 2004	Feb CAHN
>D>	AB	+		40MG/PACKET;1.68GM/PACKET	N021636	002	Dec 21, 2004	Feb CAHN
>A>	AB		SANTARUS INC	20MG/PACKET;1.68GM/PACKET	N021636	001	Jun 15, 2004	Feb CAHN
>A>	AB	+		40MG/PACKET;1.68GM/PACKET	N021636	002	Dec 21, 2004	Feb CAHN

ONDANSETRON HYDROCHLORIDE

INJECTABLE;INJECTION

ONDANSETRON HYDROCHLORIDE

		@	LANNETT	EQ 2MG BASE/ML	A090116	001	Apr 14, 2010	Jan DISC

TABLET;ORAL

ONDANSETRON HYDROCHLORIDE

	AB		IPCA LABS LTD	EQ 4MG BASE	A203761	001	Jan 23, 2014	Jan NEWA
	AB			EQ 8MG BASE	A203761	002	Jan 23, 2014	Jan NEWA

OXACILLIN SODIUM

INJECTABLE;INJECTION

OXACILLIN SODIUM

>D>		@	IBI	EQ 1GM BASE/VIAL	A062798	001	Dec 11, 1995	Feb CAHN
>D>		@		EQ 2GM BASE/VIAL	A062798	002	Dec 11, 1995	Feb CAHN
>D>		@		EQ 125MG BASE/VIAL	A062798	003	Dec 11, 1995	Feb CAHN
>D>		@		EQ 250MG BASE/VIAL	A062798	004	Dec 11, 1995	Feb CAHN

		INJECTABLE;INJECTION						
		OXACILLIN SODIUM						
>D>		@	EQ 500MG BASE/VIAL	A062798	005	Dec 11, 1995	Feb	CAHN
>A>		@ ISTITUTO BIO ITA SPA	EQ 1GM BASE/VIAL	A062798	001	Dec 11, 1995	Feb	CAHN
>A>		@	EQ 2GM BASE/VIAL	A062798	002	Dec 11, 1995	Feb	CAHN
>A>		@	EQ 125MG BASE/VIAL	A062798	003	Dec 11, 1995	Feb	CAHN
>A>		@	EQ 250MG BASE/VIAL	A062798	004	Dec 11, 1995	Feb	CAHN
>A>		@	EQ 500MG BASE/VIAL	A062798	005	Dec 11, 1995	Feb	CAHN
>A>		@ MARSAM PHARMS	EQ 1GM BASE/VIAL	A062856	003	Oct 26, 1988	Feb	CAHN
>A>		@	EQ 2GM BASE/VIAL	A062856	004	Oct 26, 1988	Feb	CAHN
>A>		@	EQ 4GM BASE/VIAL	A062856	005	Oct 26, 1988	Feb	CAHN
>A>		@	EQ 250MG BASE/VIAL	A062856	001	Oct 26, 1988	Feb	CAHN
>A>		@	EQ 500MG BASE/VIAL	A062856	002	Oct 26, 1988	Feb	CAHN
>D>		@ WATSON LABS	EQ 1GM BASE/VIAL	A062856	003	Oct 26, 1988	Feb	CAHN
>D>		@	EQ 2GM BASE/VIAL	A062856	004	Oct 26, 1988	Feb	CAHN
>D>		@	EQ 4GM BASE/VIAL	A062856	005	Oct 26, 1988	Feb	CAHN
>D>		@	EQ 250MG BASE/VIAL	A062856	001	Oct 26, 1988	Feb	CAHN
>D>		@	EQ 500MG BASE/VIAL	A062856	002	Oct 26, 1988	Feb	CAHN
		OXANDROLONE						
		TABLET;ORAL						
		OXANDRIN						
	AB	CREALTA PHARMS LLC	2.5MG	N013718	001		Jan	CAHN
	AB	+	10MG	N013718	002	Nov 05, 2001	Jan	CAHN
		OXCARBAZEPINE						
		TABLET;ORAL						
		OXCARBAZEPINE						
		@ ANI PHARMS INC	150MG	A078005	001	Dec 11, 2007	Jan	CAHN
		@	300MG	A078005	002	Dec 11, 2007	Jan	CAHN
		@	600MG	A078005	003	Dec 11, 2007	Jan	CAHN
		OXYBUTYNIN						
		FILM, EXTENDED RELEASE;TRANSDERMAL						
>A>		OXYBUTYNIN						
>A>	AB	BARR LABS DIV TEVA	3.9MG/24HR	A090526	001	Mar 04, 2014	Feb	NEWA
		OXYTROL						
>D>	+	WATSON LABS (UTAH)	3.9MG/24HR	N021351	002	Feb 26, 2003	Feb	CFTG
>A>	AB +		3.9MG/24HR	N021351	002	Feb 26, 2003	Feb	CFTG
		OXYTOCIN						
		SOLUTION;NASAL						
		SYNTOCINON						
>D>		@ NOVARTIS	40USP UNITS/ML	N012285	001		Feb	CAHN
>A>		@ RETROPHIN INC	40USP UNITS/ML	N012285	001		Feb	CAHN
		PAMIDRONATE DISODIUM						
		INJECTABLE;INJECTION						
		PAMIDRONATE DISODIUM						
		@ MN PHARMS	30MG/VIAL	A078300	001	Mar 10, 2009	Jan	DISC
		@	90MG/VIAL	A078300	002	Mar 10, 2009	Jan	DISC
		PAROXETINE HYDROCHLORIDE						
		CAPSULE;ORAL						
		PAXIL						
>A>		@ APOTEX TECNOLOGIES	EQ 10MG BASE	N020885	001	Oct 09, 1998	Feb	CAHN
>A>		@	EQ 20MG BASE	N020885	002	Oct 09, 1998	Feb	CAHN
>A>		@	EQ 30MG BASE	N020885	003	Oct 09, 1998	Feb	CAHN
>A>		@	EQ 40MG BASE	N020885	004	Oct 09, 1998	Feb	CAHN
>D>		@ GLAXOSMITHKLINE	EQ 10MG BASE	N020885	001	Oct 09, 1998	Feb	CAHN
>D>		@	EQ 20MG BASE	N020885	002	Oct 09, 1998	Feb	CAHN
>D>		@	EQ 30MG BASE	N020885	003	Oct 09, 1998	Feb	CAHN
>D>		@	EQ 40MG BASE	N020885	004	Oct 09, 1998	Feb	CAHN
		SUSPENSION;ORAL						
		PAXIL						
>A>	AB +	APOTEX TECNOLOGIES	EQ 10MG BASE/5ML	N020710	001	Jun 25, 1997	Feb	CAHN
>D>	AB +	GLAXOSMITHKLINE	EQ 10MG BASE/5ML	N020710	001	Jun 25, 1997	Feb	CAHN
		TABLET;ORAL						
		PAXIL						
	AB	APOTEX TECNOLOGIES	EQ 10MG BASE	N020031	001	Dec 29, 1992	Jan	CAHN
	AB		EQ 20MG BASE	N020031	002	Dec 29, 1992	Jan	CAHN
	AB		EQ 30MG BASE	N020031	003	Dec 29, 1992	Jan	CAHN

		TABLET;ORAL						
		PAXIL						
	AB	+	EQ 40MG BASE	N020031	005	Dec 29, 1992	Jan CAHN
		@	EQ 50MG BASE	N020031	004	Dec 29, 1992	Jan CAHN
		TABLET, EXTENDED RELEASE;ORAL						
		PAXIL CR						
>A>	AB	APOTEX TECNOLOGIES	EQ 12.5MG BASE	N020936	001	Feb 16, 1999	Feb CAHN
>A>	AB		EQ 25MG BASE	N020936	002	Feb 16, 1999	Feb CAHN
>A>	AB	+	EQ 37.5MG BASE	N020936	003	Dec 06, 2000	Feb CAHN
>D>	AB	GLAXOSMITHKLINE	EQ 12.5MG BASE	N020936	001	Feb 16, 1999	Feb CAHN
>D>	AB		EQ 25MG BASE	N020936	002	Feb 16, 1999	Feb CAHN
>D>	AB	+	EQ 37.5MG BASE	N020936	003	Dec 06, 2000	Feb CAHN
		PENICILLIN G POTASSIUM						
		INJECTABLE;INJECTION						
		PENICILLIN G POTASSIUM						
>D>	AP	IBI	5,000,000 UNITS/VIAL	A065448	001	Aug 18, 2009	Feb CAHN
>D>	AP		20,000,000 UNITS/VIAL	A065448	002	Aug 18, 2009	Feb CAHN
>A>	AP	ISTITUTO BIO ITA SPA	5,000,000 UNITS/VIAL	A065448	001	Aug 18, 2009	Feb CAHN
>A>	AP		20,000,000 UNITS/VIAL	A065448	002	Aug 18, 2009	Feb CAHN
		PERINDOPRIL ERBUMINE						
		TABLET;ORAL						
		PERINDOPRIL ERBUMINE						
	AB	ANI PHARMS INC	2MG	A078138	001	Nov 10, 2009	Jan CAHN
	AB		4MG	A078138	002	Nov 10, 2009	Jan CAHN
	AB		8MG	A078138	003	Nov 10, 2009	Jan CAHN
		PHENTERMINE HYDROCHLORIDE						
		CAPSULE;ORAL						
		PHENTERMINE HYDROCHLORIDE						
>A>	AA	INVAGEN PHARMS	15MG	A202858	001	Feb 14, 2014	Feb NEWA
>A>	AA		30MG	A202858	002	Feb 14, 2014	Feb NEWA
	AA		37.5MG	A202846	001	Feb 05, 2014	Jan NEWA
		TABLET;ORAL						
		PHENTERMINE HYDROCHLORIDE						
	AA	INVAGEN PHARMS	37.5MG	A202942	001	Feb 05, 2014	Jan NEWA
		PHENYTOIN SODIUM						
		CAPSULE;ORAL						
		EXTENDED PHENYTOIN SODIUM						
		@ ANI PHARMS INC	100MG EXTENDED	A089441	001	Dec 18, 1986	Jan CAHN
		PROMPT PHENYTOIN SODIUM						
		@ ANI PHARMS INC	100MG PROMPT	A080259	001		Jan CAHN
		PINDOLOL						
		TABLET;ORAL						
		PINDOLOL						
>D>		@ MUTUAL PHARM	5MG	A074063	001	Jan 27, 1994	Feb CMFD
>A>	AB		5MG	A074063	001	Jan 27, 1994	Feb CMFD
>D>		@	10MG	A074063	002	Jan 27, 1994	Feb CMFD
>A>	AB		10MG	A074063	002	Jan 27, 1994	Feb CMFD
>D>		MYLAN PHARMS INC	5MG	A074019	001	Sep 03, 1992	Feb CTEC
>A>	AB		5MG	A074019	001	Sep 03, 1992	Feb CTEC
>D>		+	10MG	A074019	002	Sep 03, 1992	Feb CTEC
>A>	AB	+	10MG	A074019	002	Sep 03, 1992	Feb CTEC
		PIPERACILLIN SODIUM						
		INJECTABLE;INJECTION						
		PIPERACILLIN						
>D>		+ IBI	EQ 2GM BASE/VIAL	A065114	001	Nov 14, 2003	Feb CAHN
>D>		+	EQ 3GM BASE/VIAL	A065114	002	Nov 14, 2003	Feb CAHN
>D>		+	EQ 4GM BASE/VIAL	A065114	003	Nov 14, 2003	Feb CAHN
>D>		+	EQ 40GM BASE/VIAL	A065157	001	Jul 12, 2004	Feb CAHN
>A>		+ ISTITUTO BIO ITA SPA	EQ 2GM BASE/VIAL	A065114	001	Nov 14, 2003	Feb CAHN
>A>		+	EQ 3GM BASE/VIAL	A065114	002	Nov 14, 2003	Feb CAHN
>A>		+	EQ 4GM BASE/VIAL	A065114	003	Nov 14, 2003	Feb CAHN
>A>		+	EQ 40GM BASE/VIAL	A065157	001	Jul 12, 2004	Feb CAHN

PIPERACILLIN SODIUM; TAZOBACTAM SODIUM

INJECTABLE;INJECTION

PIPERACILLIN AND TAZOBACTAM

>D>	AP		IBI	EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL	A065523	001	May 31, 2011	Feb	CAHN
>D>	AP			EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL	A065523	002	May 31, 2011	Feb	CAHN
>D>	AP			EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL	A065523	003	May 31, 2011	Feb	CAHN
>D>	AP			EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL	A090498	001	May 31, 2011	Feb	CAHN
>A>	AP		ISTITUTO BIO ITA SPA	EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL	A065523	001	May 31, 2011	Feb	CAHN
>A>	AP			EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL	A065523	002	May 31, 2011	Feb	CAHN
>A>	AP			EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL	A065523	003	May 31, 2011	Feb	CAHN
>A>	AP			EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL	A090498	001	May 31, 2011	Feb	CAHN

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE ANHYDROUS

FOR SUSPENSION;ORAL

CO-LAV

>D>		@	BOCA PHARMA LLC	240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT	A073428	001	Jan 28, 1992	Feb	CAHN
>A>		@	VINTAGE PHARMS	240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT	A073428	001	Jan 28, 1992	Feb	CAHN

GO-EVAC

>D>		@	BOCA PHARMA LLC	236GM/BOT;2.97GM/BOT;6.74GM/BOT;5.86GM/BOT;22.74GM/BOT	A073433	001	Apr 28, 1992	Feb	CAHN
>A>		@	VINTAGE PHARMS	236GM/BOT;2.97GM/BOT;6.74GM/BOT;5.86GM/BOT;22.74GM/BOT	A073433	001	Apr 28, 1992	Feb	CAHN

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

MIRAPEX ER

	AB	+	BOEHRINGER INGELHEIM	0.375MG	N022421	001	Feb 19, 2010	Jan	CFTG
	AB			0.75MG	N022421	002	Feb 19, 2010	Jan	CFTG
	AB			1.5MG	N022421	003	Feb 19, 2010	Jan	CFTG
	AB			2.25MG	N022421	006	Jun 17, 2011	Jan	CFTG
	AB			3MG	N022421	004	Feb 19, 2010	Jan	CFTG
	AB			3.75MG	N022421	007	Jun 17, 2011	Jan	CFTG
	AB			4.5MG	N022421	005	Feb 19, 2010	Jan	CFTG

PRAMIPEXOLE DIHYDROCHLORIDE

	AB		ANCHEN PHARMS	0.375MG	A202206	001	Feb 06, 2014	Jan	NEWA
	AB			0.75MG	A202206	002	Feb 06, 2014	Jan	NEWA
	AB			1.5MG	A202206	003	Feb 06, 2014	Jan	NEWA
	AB			2.25MG	A202206	004	Feb 06, 2014	Jan	NEWA
	AB			3MG	A202206	005	Feb 06, 2014	Jan	NEWA
	AB			3.75MG	A202206	006	Feb 06, 2014	Jan	NEWA
	AB			4.5MG	A202206	007	Feb 06, 2014	Jan	NEWA

PRAMLINTIDE ACETATE

INJECTABLE;SUBCUTANEOUS

SYMLIN

>D>			AMYLIN PHARMS LLC	EQ 1.5MG BASE/1.5ML (EQ 1MG BASE/ML)	N021332	002	Sep 25, 2007	Feb	CAHN
>D>		+		EQ 2.7MG BASE/2.7ML (EQ 1MG BASE/ML)	N021332	003	Sep 25, 2007	Feb	CAHN
>D>		@		EQ 3MG BASE/5ML (EQ 600MCG BASE/ML)	N021332	001	Mar 16, 2005	Feb	CAHN
>A>			ASTRAZENECA AB	EQ 1.5MG BASE/1.5ML (EQ 1MG BASE/ML)	N021332	002	Sep 25, 2007	Feb	CAHN
>A>		+		EQ 2.7MG BASE/2.7ML (EQ 1MG BASE/ML)	N021332	003	Sep 25, 2007	Feb	CAHN
>A>		@		EQ 3MG BASE/5ML (EQ 600MCG BASE/ML)	N021332	001	Mar 16, 2005	Feb	CAHN

PREDNISOLONE SODIUM PHOSPHATE; SULFACETAMIDE SODIUM

SOLUTION/DROPS;OPHTHALMIC

SULFACETAMIDE SODIUM AND PREDNISOLONE SODIUM PHOSPHATE

>D>	AT		BAUSCH AND LOMB	EQ 0.23% PHOSPHATE;10%	A074449	001	Dec 29, 1995	Feb	CRLD
>A>	AT	+		EQ 0.23% PHOSPHATE;10%	A074449	001	Dec 29, 1995	Feb	CRLD

			SOLUTION/DROPS;OPHTHALMIC						
>D>			VASOCIDIN						
>D>	AT	+	NOVARTIS	EQ 0.23% PHOSPHATE;10%	N018988	001	Aug 26, 1988	Feb	DISC
>A>		@		EQ 0.23% PHOSPHATE;10%	N018988	001	Aug 26, 1988	Feb	DISC
			PRIMAQUINE PHOSPHATE						
			TABLET;ORAL						
			PRIMAQUINE						
	AB	+	SANOFI AVENTIS US	EQ 15MG BASE	N008316	001		Jan	CFTG
			PRIMAQUINE PHOSPHATE						
	AB		ALVOGEN INC	EQ 15MG BASE	A203924	001	Feb 03, 2014	Jan	NEWA
>A>	AB		BAYSHORE PHARMS LLC	EQ 15MG BASE	A204476	001	Feb 25, 2014	Feb	NEWA
			PROCAINAMIDE HYDROCHLORIDE						
			TABLET, EXTENDED RELEASE;ORAL						
			PROCAINAMIDE HYDROCHLORIDE						
		@	ANI PHARMS INC	1GM	A040111	001	Dec 13, 1996	Jan	CAHN
		@		250MG	A088958	001	Dec 02, 1985	Jan	CAHN
		@		500MG	A088959	001	Dec 02, 1985	Jan	CAHN
		@		750MG	A089438	001	Mar 23, 1987	Jan	CAHN
			PROPAFENONE HYDROCHLORIDE						
			TABLET;ORAL						
			PROPAFENONE HYDROCHLORIDE						
	AB		ANI PHARMS INC	150MG	A076550	001	Apr 23, 2004	Jan	CAHN
	AB			225MG	A076550	002	Apr 23, 2004	Jan	CAHN
	AB			300MG	A076550	003	Apr 23, 2004	Jan	CAHN
			PROPRANOLOL HYDROCHLORIDE						
			TABLET;ORAL						
			INDERAL						
		@	WYETH PHARMS INC	40MG	N016418	002		Jan	DISC
		@		60MG	N016418	009	Oct 18, 1982	Jan	DISC
		@		80MG	N016418	004		Jan	DISC
			PROPRANOLOL HYDROCHLORIDE						
		@	ANI PHARMS INC	90MG	A071977	001	Apr 06, 1988	Jan	CAHN
			PROPYLTHIOURACIL						
			TABLET;ORAL						
			PROPYLTHIOURACIL						
		@	ANI PHARMS INC	50MG	A080215	001		Jan	CAHN
			RALOXIFENE HYDROCHLORIDE						
			TABLET;ORAL						
			EVISTA						
>D>		+	LILLY	60MG	N020815	001	Dec 09, 1997	Feb	CFTG
>A>	AB	+		60MG	N020815	001	Dec 09, 1997	Feb	CFTG
>A>			RALOXIFENE HYDROCHLORIDE						
>A>	AB		TEVA PHARMS USA	60MG	A078193	001	Mar 04, 2014	Feb	NEWA
			RANITIDINE HYDROCHLORIDE						
>D>			TABLET, EFFERVESCENT;ORAL						
>D>			ZANTAC 25						
>D>		+	GLAXO GRP LTD	EQ 25MG BASE	N020251	003	Apr 01, 2004	Feb	DISC
>A>		@		EQ 25MG BASE	N020251	003	Apr 01, 2004	Feb	DISC
			REPAGLINIDE						
			TABLET;ORAL						
			REPAGLINIDE						
	AB		ACTAVIS TOTOWA	0.5MG	A090008	001	Jan 22, 2014	Jan	NEWA
	AB			1MG	A090008	002	Jan 22, 2014	Jan	NEWA
	AB			2MG	A090008	003	Jan 22, 2014	Jan	NEWA
	AB		AUROBINDO PHARMA LTD	0.5MG	A203820	001	Jan 22, 2014	Jan	NEWA
	AB			1MG	A203820	002	Jan 22, 2014	Jan	NEWA
	AB			2MG	A203820	003	Jan 22, 2014	Jan	NEWA
	AB		MYLAN PHARMS INC	1MG	A090252	002	Jan 22, 2014	Jan	NEWA
	AB			2MG	A090252	003	Jan 22, 2014	Jan	NEWA
	AB		PADDOCK LLC	1MG	A201189	002	Jan 22, 2014	Jan	NEWA
	AB			2MG	A201189	003	Jan 22, 2014	Jan	NEWA
	AB		SANDOZ	1MG	A078555	002	Jan 22, 2014	Jan	NEWA
	AB			2MG	A078555	003	Jan 22, 2014	Jan	NEWA

RIFABUTIN

CAPSULE;ORAL

MYCOBUTIN

>D>		+	PHARMACIA AND UPJOHN	150MG	N050689	001	Dec 23, 1992	Feb CFTG
>A>	AB	+		150MG	N050689	001	Dec 23, 1992	Feb CFTG

RIFABUTIN

>A>	AB		LUPIN LTD	150MG	A090033	001	Feb 24, 2014	Feb NEWA

RISPERIDONE

SOLUTION;ORAL

RISPERIDONE

	AA		ANI PHARMS INC	1MG/ML	A076440	001	Jan 30, 2009	Jan CAHN

TABLET;ORAL

RISPERIDONE

>A>	AB		CARACO	0.25MG	A078036	001	Mar 10, 2014	Feb NEWA
>A>	AB			0.5MG	A078036	002	Mar 10, 2014	Feb NEWA
>A>	AB			1MG	A078036	003	Mar 10, 2014	Feb NEWA
>A>	AB			2MG	A078036	004	Mar 10, 2014	Feb NEWA
>A>	AB			3MG	A078036	005	Mar 10, 2014	Feb NEWA
>A>	AB			4MG	A078036	006	Mar 10, 2014	Feb NEWA

RIZATRIPTAN BENZOATE

TABLET;ORAL

RIZATRIPTAN BENZOATE

	AB		MACLEODS PHARMS LTD	EQ 5MG BASE	A203147	001	Feb 11, 2014	Jan NEWA
	AB			EQ 10MG BASE	A203147	002	Feb 11, 2014	Jan NEWA

SIMEPREVIR

CAPSULE;ORAL

OLYSIO

>D>		+	JANSSEN RES AND DEV	150MG	N205123	001	Nov 22, 2013	Feb CAIN

SIMEPREVIR SODIUM

CAPSULE;ORAL

OLYSIO

>A>		+	JANSSEN RES AND DEV	EQ 150MG BASE	N205123	001	Nov 22, 2013	Feb CAIN

SOMATROPIN RECOMBINANT

INJECTABLE;INJECTION

ACCRETROPIN

>D>		@	CANGENE	5MG/ML (5MG/ML)	N021538	001	Jan 23, 2008	Feb CAHN
>A>		@	EMERGENT	5MG/ML (5MG/ML)	N021538	001	Jan 23, 2008	Feb CAHN

SPIRONOLACTONE

TABLET;ORAL

SPIRONOLACTONE

>A>	AB		ORION CORP ORION	25MG	A202187	001	Mar 06, 2014	Feb NEWA
>A>	AB			50MG	A202187	002	Mar 06, 2014	Feb NEWA
>A>	AB			100MG	A202187	003	Mar 06, 2014	Feb NEWA

SUMATRIPTAN SUCCINATE

INJECTABLE;SUBCUTANEOUS

SUMATRIPTAN SUCCINATE

	AB		DR REDDYS LABS INC	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A090495	001	Jan 29, 2014	Jan NEWA

SUNITINIB MALATE

CAPSULE;ORAL

SUNITINIB MALATE

	AB		MYLAN PHARMS INC	EQ 12.5MG BASE	A201275	001	Jan 30, 2014	Jan NEWA
	AB			EQ 25MG BASE	A201275	002	Jan 30, 2014	Jan NEWA
	AB			EQ 37.5MG BASE	A201275	003	Jan 30, 2014	Jan NEWA
	AB			EQ 50MG BASE	A201275	004	Jan 30, 2014	Jan NEWA

SUTENT

	AB		CPPI CV	EQ 12.5MG BASE	N021938	001	Jan 26, 2006	Jan CFTG
	AB			EQ 25MG BASE	N021938	002	Jan 26, 2006	Jan CFTG
	AB			EQ 37.5MG BASE	N021938	004	Mar 31, 2009	Jan CFTG
	AB	+		EQ 50MG BASE	N021938	003	Jan 26, 2006	Jan CFTG

TASIMELTEON

CAPSULE;ORAL

HETLIOZ

	+	VANDA PHARMS INC	20MG		N205677	001	Jan 31, 2014	Jan NEWA

TEMOZOLOMIDE

CAPSULE;ORAL

TEMOZOLOMIDE

>A>	AB		SUN PHARMA GLOBAL	5MG	A201742	001	Feb 12, 2014	Feb NEWA
>A>	AB			20MG	A201742	002	Feb 12, 2014	Feb NEWA
>A>	AB			100MG	A201742	003	Feb 12, 2014	Feb NEWA
>A>	AB			140MG	A201742	004	Feb 12, 2014	Feb NEWA
>A>	AB			180MG	A201742	005	Feb 12, 2014	Feb NEWA
>A>	AB			250MG	A201742	006	Feb 12, 2014	Feb NEWA

THEOPHYLLINE

TABLET, EXTENDED RELEASE;ORAL

THEOCHRON

		@	CARACO	300MG	A087400	002	Jan 11, 1983	Jan DISC

THIORIDAZINE HYDROCHLORIDE

CONCENTRATE;ORAL

THIORIDAZINE HYDROCHLORIDE

>A>		@	ANI PHARMS INC	100MG/ML	A089603	001	Nov 09, 1987	Feb CAHN
>D>		@	TEVA PHARMS	100MG/ML	A089603	001	Nov 09, 1987	Feb CAHN

TABLET;ORAL

THIORIDAZINE HYDROCHLORIDE

>A>		@	ANI PHARMS INC	10MG	A088270	001	Apr 14, 1983	Feb CAHN
>A>		@		10MG	A088493	001	May 17, 1985	Feb CAHN
>A>		@		15MG	A088271	001	Apr 14, 1983	Feb CAHN
>A>		@		25MG	A088272	001	Apr 14, 1983	Feb CAHN
>A>		@		50MG	A088194	001	Apr 14, 1983	Feb CAHN
>A>		@		100MG	A088273	001	Oct 03, 1983	Feb CAHN
>A>		@		100MG	A088456	001	May 17, 1985	Feb CAHN
>D>		@	IVAX PHARMS	10MG	A088270	001	Apr 14, 1983	Feb CAHN
>D>		@		15MG	A088271	001	Apr 14, 1983	Feb CAHN
>D>		@		25MG	A088272	001	Apr 14, 1983	Feb CAHN
>D>		@		50MG	A088194	001	Apr 14, 1983	Feb CAHN
>D>		@		100MG	A088273	001	Oct 03, 1983	Feb CAHN
>D>		@	TEVA	10MG	A088493	001	May 17, 1985	Feb CAHN
>D>		@		100MG	A088456	001	May 17, 1985	Feb CAHN

TRANEXAMIC ACID

INJECTABLE;INJECTION

TRANEXAMIC ACID

	AP		ACIC FINE CHEMS	100MG/ML	A202436	001	Feb 11, 2014	Jan NEWA

TABLET;ORAL

TRANEXAMIC ACID

	AB		APOTEX INC	650 MG	A202286	001	Jan 27, 2014	Jan NEWA

TRAVOPROST

SOLUTION/DROPS;OPHTHALMIC

TRAVOPROST

>D>			PAR PHARM	0.004%	A091340	001	Mar 01, 2013	Feb CRLD
>A>		+		0.004%	A091340	001	Mar 01, 2013	Feb CRLD

TRETINOIN

GEL;TOPICAL

RETIN-A-MICRO

		+	VALEANT INTL	0.08%	N020475	003	Jan 28, 2014	Jan NEWA

SOLUTION;TOPICAL

RETIN-A

>D>	AT	+	VALEANT INTL	0.05%	N016921	001		Feb CTEC
>A>		+		0.05%	N016921	001		Feb CTEC

>D>			TRETINOIN					
>D>	AT		WOCKHARDT	0.05%	A075260	001	Jan 25, 1999	Feb DISC
>A>		@		0.05%	A075260	001	Jan 25, 1999	Feb DISC

VALACYCLOVIR HYDROCHLORIDE

TABLET;ORAL

VALACYCLOVIR HYDROCHLORIDE

AB	CIPLA LTD	EQ 1GM BASE	A077135	002	May 24, 2010	Jan	CAHN
AB		EQ 500MG BASE	A077135	001	May 24, 2010	Jan	CAHN

VALPROIC ACID

SYRUP;ORAL

VALPROIC ACID

AA	ANI PHARMS INC	250MG/5ML	A073178	001	Aug 25, 1992	Jan	CAHN

VANCOMYCIN HYDROCHLORIDE

INJECTABLE;INJECTION

VANCOMYCIN HYDROCHLORIDE

>A> AP	AGILA SPECLTS	EQ 10GM BASE/VIAL	A091554	001	Sep 19, 2011	Feb	CAHN
>D> AP	STRIDES ARCOLAB LTD	EQ 10GM BASE/VIAL	A091554	001	Sep 19, 2011	Feb	CAHN

ZICONOTIDE

INJECTABLE;INTRATHECAL

PRIALT

>D>	@ JAZZ PHARMS INTL	200MCG/2ML (100MCG/ML)	N021060	003	Dec 28, 2004	Feb	CAIN

ZICONOTIDE ACETATE

INJECTABLE;INTRATHECAL

PRIALT

>A>	@ JAZZ PHARMS INTL	200MCG/2ML (100MCG/ML)	N021060	003	Dec 28, 2004	Feb	CAIN

ZOLMITRIPTAN

TABLET;ORAL

ZOLMITRIPTAN

>A> AB	TEVA PHARMS USA	2.5MG	A090861	001	Mar 04, 2014	Feb	NEWA
>A> AB		5MG	A090861	002	Mar 04, 2014	Feb	NEWA

ZONISAMIDE

CAPSULE;ORAL

ZONISAMIDE

AB	ANI PHARMS INC	25MG	A077639	001	Dec 22, 2005	Jan	CAHN
@		25MG	A077641	003	Dec 22, 2005	Jan	CAHN
AB		50MG	A077639	002	Dec 22, 2005	Jan	CAHN
@		50MG	A077641	002	Dec 22, 2005	Jan	CAHN
AB		100MG	A077639	003	Dec 22, 2005	Jan	CAHN
@		100MG	A077641	001	Dec 22, 2005	Jan	CAHN
>D> AB	SANDOZ	25MG	A077644	001	Dec 22, 2005	Feb	DISC
>A> @		25MG	A077644	001	Dec 22, 2005	Feb	DISC
>D> AB		50MG	A077644	002	Dec 22, 2005	Feb	DISC
>A> @		50MG	A077644	002	Dec 22, 2005	Feb	DISC
>D> AB		100MG	A077644	003	Dec 22, 2005	Feb	DISC
>A> @		100MG	A077644	003	Dec 22, 2005	Feb	DISC

>D>	ACETAMINOPHEN; DEXBROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE						
>D>	TABLET, EXTENDED RELEASE;ORAL						
>D>	DRIXORAL PLUS						
>D>	+ SCHERING PLOUGH	500MG;3MG;60MG	N019453	001	May 22, 1987	Feb	DISC
>A>	@	500MG;3MG;60MG	N019453	001	May 22, 1987	Feb	DISC
	CETIRIZINE HYDROCHLORIDE						
	TABLET;ORAL						
	CETIRIZINE HYDROCHLORIDE ALLERGY						
>A>	IPCA LABS LTD	5MG	A202277	002	Mar 11, 2014	Feb	NEWA
>A>		10MG	A202277	004	Mar 11, 2014	Feb	NEWA
	CETIRIZINE HYDROCHLORIDE HIVES						
>A>	IPCA LABS LTD	5MG	A202277	001	Mar 11, 2014	Feb	NEWA
>A>		10MG	A202277	003	Mar 11, 2014	Feb	NEWA
	TABLET, CHEWABLE;ORAL						
>D>	CETIRIZINE HYDROCHLORIDE ALLERGY						
>D>	CARACO	5MG	A077631	004	Jan 11, 2008	Feb	DISC
>A>	@	5MG	A077631	004	Jan 11, 2008	Feb	DISC
>D>		10MG	A077631	003	Jan 11, 2008	Feb	DISC
>A>	@	10MG	A077631	003	Jan 11, 2008	Feb	DISC
>D>	CETIRIZINE HYDROCHLORIDE HIVES RELIEF						
>D>	CARACO	5MG	A077631	001	Jan 11, 2008	Feb	DISC
>A>	@	5MG	A077631	001	Jan 11, 2008	Feb	DISC
>D>		10MG	A077631	002	Jan 11, 2008	Feb	DISC
>A>	@	10MG	A077631	002	Jan 11, 2008	Feb	DISC
	DEXBROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE						
	TABLET, EXTENDED RELEASE;ORAL						
	DEXBROMPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE SULFATE						
	+ AVANTHI INC	6MG;120MG	A078648	001	Feb 27, 2013	Jan	CRLD
	DISOPHROL						
	@ SCHERING PLOUGH	6MG;120MG	N013483	004	Sep 13, 1982	Jan	DISC
	DRIXORAL						
	@ SCHERING PLOUGH	6MG;120MG	N013483	003	Sep 13, 1982	Jan	DISC
	DIPHENHYDRAMINE HYDROCHLORIDE; NAPROXEN SODIUM						
	TABLET;ORAL						
	ALEVE PM						
	+ BAYER HLTHCARE	25MG;220MG	N205352	001	Jan 17, 2014	Jan	NEWA
	MINOXIDIL						
	AEROSOL, FOAM;TOPICAL						
>A>	WOMEN'S ROGAINE						
>A>	+ JOHNSON AND JOHNSON	5%	N021812	002	Feb 28, 2014	Feb	NEWA

DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST

CUMULATIVE SUPPLEMENT NUMBER 2 FEBRUARY 2014

NO FEBRUARY 2014 APPROVALS

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of List of Orphan Designations and Approvals is available at:

http://www.fda.gov/orphan/designat/list.htm

DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION

NO FEBRUARY 2014 ADDITIONS

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2014

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ACETYLCYSTEINE - ACETADOTE							
N 021539 001	>A>	8653061	Aug 24, 2025	U-1373			
ACYCLOVIR; HYDROCORTISONE - XERESE							
N 022436 001	>A>	6514980	Jan 24, 2019	DP U-1006		NPP	Jan 22, 2017
	>A>	6514980	Jan 24, 2019	DP U-1484			
	>A>	7223387	May 13, 2023	DP U-1006			
	>A>	7223387	May 13, 2023	DP U-1484			
	>A>	RE39264	Aug 02, 2016	DP U-1006			
	>A>	RE39264	Aug 02, 2016	DP U-1484			
ALISKIREN HEMIFUMARATE - TEKTURNA							
N 021985 001		8617595	Feb 19, 2026	DP			
ALISKIREN HEMIFUMARATE - TEKTURNA							
N 021985 002		8617595	Feb 19, 2026	DP			
ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO							
N 022545 001		8613949	Dec 21, 2029	DP			
ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO							
N 022545 002		8613949	Dec 21, 2029	DP			
ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO							
N 022545 003		8613949	Dec 21, 2029	DP			
ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO							
N 022545 004		8613949	Dec 21, 2029	DP			
ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE							
N 200045 001		8618174	Nov 15, 2021	DP			
ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE							
N 200045 002		8618174	Nov 15, 2021	DP			
ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE							
N 200045 003		8618174	Nov 15, 2021	DP			
ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE							
N 200045 004		8618174	Nov 15, 2021	DP			
ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE							
N 200045 005		8618174	Nov 15, 2021	DP			
ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE - TEKTURNA HCT							
N 022107 001		8618172	Jul 13, 2028	DP			
ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE - TEKTURNA HCT							
N 022107 002		8618172	Jul 13, 2028	DP			
ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE - TEKTURNA HCT							
N 022107 003		8618172	Jul 13, 2028	DP			
ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE - TEKTURNA HCT							
N 022107 004		8618172	Jul 13, 2028	DP			
ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI							
N 022426 001	>A>	8637079	Jan 23, 2029	DP			
ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI							
N 022426 002	>A>	8637079	Jan 23, 2029	DP			
ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI							
N 022426 003	>A>	8637079	Jan 23, 2029	DP			
ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI							
N 022426 004	>A>	8637079	Jan 23, 2029	DP			
ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI							
N 022426 005	>A>	8637079	Jan 23, 2029	DP			
ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI							
N 022426 006	>A>	8637079	Jan 23, 2029	DP			
ALVIMOPAN - ENTEREG							
N 021775 001	>A>	8645160	Jun 18, 2029	U-1485			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ARIPIPRAZOLE - ABILIFY						
N 021436 001	>A> 8642600	Jan 28, 2022	U-1492			
	>A> 8642600*PED	Jul 28, 2022				
	>A> 8642760	Sep 25, 2022	DS			
	>A> 8642760*PED	Mar 25, 2023				
ARIPIPRAZOLE - ABILIFY						
N 021436 002	>A> 8642600	Jan 28, 2022	U-1492			
	>A> 8642600*PED	Jul 28, 2022				
	>A> 8642760	Sep 25, 2022	DS			
	>A> 8642760*PED	Mar 25, 2023				
ARIPIPRAZOLE - ABILIFY						
N 021436 003	>A> 8642600	Jan 28, 2022	U-1492			
	>A> 8642600*PED	Jul 28, 2022				
	>A> 8642760	Sep 25, 2022	DS			
	>A> 8642760*PED	Mar 25, 2023				
ARIPIPRAZOLE - ABILIFY						
N 021436 004	>A> 8642600	Jan 28, 2022	U-1492			
	>A> 8642600*PED	Jul 28, 2022				
	>A> 8642760	Sep 25, 2022	DS			
	>A> 8642760*PED	Mar 25, 2023				
ARIPIPRAZOLE - ABILIFY						
N 021436 005	>A> 8642600	Jan 28, 2022	U-1492			
	>A> 8642600*PED	Jul 28, 2022				
	>A> 8642760	Sep 25, 2022	DS			
	>A> 8642760*PED	Mar 25, 2023				
ARIPIPRAZOLE - ABILIFY						
N 021436 006	>A> 8642600	Jan 28, 2022	U-1492			
	>A> 8642600*PED	Jul 28, 2022				
	>A> 8642760	Sep 25, 2022	DS			
	>A> 8642760*PED	Mar 25, 2023				
ARIPIPRAZOLE - ABILIFY						
N 021713 001	>A> 8642600	Jan 28, 2022	U-1492			
	>A> 8642600*PED	Jul 28, 2022				
ARIPIPRAZOLE - ABILIFY						
N 021729 002	>A> 8642600	Jan 28, 2022	U-1492			
	>A> 8642600*PED	Jul 28, 2022				
	>A> 8642760	Sep 25, 2022	DS			
	>A> 8642760*PED	Mar 25, 2023				
ARIPIPRAZOLE - ABILIFY						
N 021729 003	>A> 8642600	Jan 28, 2022	U-1492			
	>A> 8642600*PED	Jul 28, 2022				
	>A> 8642760	Sep 25, 2022	DS			
	>A> 8642760*PED	Mar 25, 2023				
ARIPIPRAZOLE - ABILIFY						
N 021729 004	>A> 8642600	Jan 28, 2022	U-1492			
	>A> 8642600*PED	Jul 28, 2022				
	>A> 8642760	Sep 25, 2022	DS			
	>A> 8642760*PED	Mar 25, 2023				
ARIPIPRAZOLE - ABILIFY						
N 021729 005	>A> 8642600	Jan 28, 2022	U-1492			
	>A> 8642600*PED	Jul 28, 2022				
	>A> 8642760	Sep 25, 2022	DS			
	>A> 8642760*PED	Mar 25, 2023				
BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE - ACANYA						
N 050819 001	>A> 8663699	Jun 03, 2029	U-124			
BIMATOPROST - LATISSE						
N 022369 001	>A> 8263054	Jan 15, 2023	U-1277			
	>A> 8632760	Jan 15, 2023	U-1487			
BORTEZOMIB - VELCADE						
N 021602 001					>A> ODE	Jun 20, 2015
BROMOCRIPTINE MESYLATE - CYCLOSET						
N 020866 001	8613947	Apr 30, 2032	DP U-976			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2014

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE		PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT								
N 021929 001		8616196	Apr 07, 2029		DP			
BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT								
N 021929 002		8616196	Apr 07, 2029		DP			
CABAZITAXEL - JEVTANA KIT								
N 201023 001	>A>	5847170	Mar 26, 2021	DS	DP			
CLEVIDIPINE - CLEVIPREX								
N 022156 001	>A>	8658676	Oct 10, 2031		DP			
CLEVIDIPINE - CLEVIPREX								
N 022156 002	>A>	8658676	Oct 10, 2031		DP			
CLEVIDIPINE - CLEVIPREX								
N 022156 003	>A>	5739152	Apr 14, 2015		DP U-893			
	>A>	5856346	Jan 05, 2021	DS	DP U-893			
	>A>	8658676	Oct 10, 2031		DP			
COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - STRIBILD								
N 203100 001		8633219	Oct 11, 2031		DP U-257		>A> NP	Aug 27, 2015
CYCLOSPORINE - RESTASIS								
N 050790 001		8633162	Aug 27, 2024		U-1479			
		8642556	Aug 27, 2024		DP			
		8648048	Aug 27, 2024		U-1483			
DABRAFENIB MESYLATE - TAFINLAR								
N 202806 001							I-678	Jan 08, 2017
							ODE	Jan 09, 2021
DABRAFENIB MESYLATE - TAFINLAR								
N 202806 002							I-678	Jan 08, 2017
							ODE	Jan 09, 2021
DAPAGLIFLOZIN - FARXIGA								
N 202293 001							NCE	Jan 08, 2019
DAPAGLIFLOZIN - FARXIGA								
N 202293 002							NCE	Jan 08, 2019
DARUNAVIR ETHANOLATE - PREZISTA								
N 021976 001		8597876	Jun 23, 2019		U-1305			
		8597876*PED	Dec 23, 2019					
DARUNAVIR ETHANOLATE - PREZISTA								
N 021976 002		8597876	Jun 23, 2019		U-1305			
		8597876*PED	Dec 23, 2019					
DARUNAVIR ETHANOLATE - PREZISTA								
N 021976 003		8597876	Jun 23, 2019		U-1305			
		8597876*PED	Dec 23, 2019					
DARUNAVIR ETHANOLATE - PREZISTA								
N 021976 004		8597876	Jun 23, 2019		U-1305			
		8597876*PED	Dec 23, 2019					
DARUNAVIR ETHANOLATE - PREZISTA								
N 021976 005		8597876	Jun 23, 2019		U-1305			
		8597876*PED	Dec 23, 2019					
DARUNAVIR ETHANOLATE - PREZISTA								
N 021976 006		8597876	Jun 23, 2019		U-1305			
		8597876*PED	Dec 23, 2019					
DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX								
N 021038 001							M-61	Jun 17, 2016
							PED	Dec 17, 2016
DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX								
N 021038 002	>A>	8648106	Jan 04, 2032		DP		M-61	Jun 17, 2016
	>A>	8648106*PED	Jul 04, 2032				PED	Dec 17, 2016
DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX								
N 021038 003	>A>	8648106	Jan 04, 2032		DP		M-61	Jun 17, 2016
	>A>	8648106*PED	Jul 04, 2032				PED	Dec 17, 2016
DEXMETHYLPHENIDATE HYDROCHLORIDE - DEXMETHYLPHENIDATE HYDROCHLORIDE								
A 078992 003							>A> PC	May 18, 2014

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2014

See List footnote for information regarding List content

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DICLOFENAC EPOLAMINE - FLECTOR								
N 021234	001	>A>	5607690	Apr 13, 2019	DP			
DICLOFENAC POTASSIUM - ZIPSOR								
N 022202	001		6287594	Jan 15, 2019	DP			
			8623920	Feb 24, 2029	U-1482			
DICLOFENAC SODIUM - PENNSAID								
N 204623	001	>A>	8217078	Jul 10, 2029	U-1477		NP	Jan 16, 2017
		>A>	8252838	Apr 21, 2028	DP U-1489			
		>A>	8546450	Aug 09, 2030	U-1435			
		>A>	8546450	Aug 09, 2030	U-1436			
		>A>	8563613	Oct 17, 2027	DP U-1488			
		>A>	8618164	Jul 10, 2029	U-1477			
DIPHENHYDRAMINE HYDROCHLORIDE; NAPROXEN SODIUM - ALEVE PM								
N 205352	001						NC	Jan 17, 2017
DROSPIRENONE; ETHINYL ESTRADIOL; LEVOMEFOLATE CALCIUM - BEYAZ								
N 022532	001		8617597	Feb 08, 2030	DP			
DROSPIRENONE; ETHINYL ESTRADIOL; LEVOMEFOLATE CALCIUM - SAFYRAL								
N 022574	001		8617597	Feb 08, 2030	DP			
DROXIDOPA - NORTHERA								
N 203202	001						>A> NCE	Feb 18, 2019
							>A> ODE	Feb 18, 2021
DROXIDOPA - NORTHERA								
N 203202	002						>A> NCE	Feb 18, 2019
							>A> ODE	Feb 18, 2021
DROXIDOPA - NORTHERA								
N 203202	003						>A> NCE	Feb 18, 2019
							>A> ODE	Feb 18, 2021
ESOMEPRAZOLE SODIUM - NEXIUM IV								
N 021689	001						>A> D-138	Mar 04, 2017
							>A> I-679	Mar 04, 2017
ESOMEPRAZOLE SODIUM - NEXIUM IV								
N 021689	002						>A> D-138	Mar 04, 2017
							>A> I-679	Mar 04, 2017
EZETIMIBE - ZETIA								
N 021445	001	>A>	7612058	Oct 30, 2025	U-1027			
		>A>	7612058	Oct 30, 2025	U-1173			
		>A>	7612058*PED	Apr 30, 2026				
FENTANYL - SUBSYS								
N 202788	001	>A>	8486972	Apr 27, 2030	DP			
		>A>	8486973	Apr 27, 2030	U-55			
FENTANYL - SUBSYS								
N 202788	002	>A>	8486972	Apr 27, 2030	DP			
		>A>	8486973	Apr 27, 2030	U-55			
FENTANYL - SUBSYS								
N 202788	003	>A>	8486972	Apr 27, 2030	DP			
		>A>	8486973	Apr 27, 2030	U-55			
FENTANYL - SUBSYS								
N 202788	004	>A>	8486972	Apr 27, 2030	DP			
		>A>	8486973	Apr 27, 2030	U-55			
FENTANYL - SUBSYS								
N 202788	005	>A>	8486972	Apr 27, 2030	DP			
		>A>	8486973	Apr 27, 2030	U-55			
FENTANYL - SUBSYS								
N 202788	006	>A>	8486972	Apr 27, 2030	DP			
		>A>	8486973	Apr 27, 2030	U-55			
FENTANYL - SUBSYS								
N 202788	007	>A>	8486972	Apr 27, 2030	DP			
		>A>	8486973	Apr 27, 2030	U-55			
FLUOCINONIDE - FLUOCINONIDE								
A 090256	001						PC	Jul 13, 2014

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FLUTICASONE FUROATE - VERAMYST						
N 022051 001	>A> 8147461	Oct 15, 2028	DP			
FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA						
N 204275 001					>A> NP	May 10, 2016
GABAPENTIN ENACARBIL - HORIZANT						
N 022399 001					ODE	Jun 06, 2019
GABAPENTIN ENACARBIL - HORIZANT						
N 022399 002					ODE	Jun 06, 2019
GLATIRAMER ACETATE - COPAXONE						
N 020622 003	>A> 6054430	May 24, 2014	DS			
	>A> 6342476	May 24, 2014	U-441			
	>A> 6362161	May 24, 2014	DS			
	>A> 7199098	May 24, 2014	DS			
	>A> 8232250	Aug 19, 2030	U-441			
	>A> 8367605	May 24, 2014	DS			
	>A> 8399413	Sep 06, 2030	U-441			
GLYCEROL PHENYLBUTYRATE - RAVICTI						
N 203284 001	>A> 8642012	Sep 22, 2030	U-1383			
HEXAMINOLEVULINATE HYDROCHLORIDE - CYSVIEW KIT						
N 022555 001	>A> 7348361	Nov 06, 2020	DP U-1087			
HYDROCODONE BITARTRATE - ZOHYDRO ER						
N 202880 001	>A> 6228398	Nov 01, 2019	DP			
HYDROCODONE BITARTRATE - ZOHYDRO ER						
N 202880 002	>A> 6228398	Nov 01, 2019	DP			
HYDROCODONE BITARTRATE - ZOHYDRO ER						
N 202880 003	>A> 6228398	Nov 01, 2019	DP			
HYDROCODONE BITARTRATE - ZOHYDRO ER						
N 202880 004	>A> 6228398	Nov 01, 2019	DP			
HYDROCODONE BITARTRATE - ZOHYDRO ER						
N 202880 005	>A> 6228398	Nov 01, 2019	DP			
HYDROCODONE BITARTRATE - ZOHYDRO ER						
N 202880 006	>A> 6228398	Nov 01, 2019	DP			
IBRUTINIB - IMBRUVICA						
N 205552 001	>A> 8476284	Dec 28, 2026	U-1456		>A> I-680	Feb 12, 2017
	>A> 8476284	Dec 28, 2026	U-1491		>A> ODE	Feb 12, 2021
	>A> 8497277	Dec 28, 2026	U-1456			
	>A> 8497277	Dec 28, 2026	U-1491			
ICOSAPENT ETHYL - VASCEPA						
N 202057 001					>A> NP	Jul 26, 2015
IMATINIB MESYLATE - GLEEVEC						
N 021335 001	RE43932	Jan 16, 2019	DS DP			
	RE43932*PED	Jul 16, 2019				
IMATINIB MESYLATE - GLEEVEC						
N 021335 002	RE43932	Jan 16, 2019	DS DP			
	RE43932*PED	Jul 16, 2019				
INDOMETHACIN - TIVORBEX						
N 204768 001					>A> NP	Feb 24, 2017
INDOMETHACIN - TIVORBEX						
N 204768 002					>A> NP	Feb 24, 2017
INSULIN ASPART RECOMBINANT - NOVOLOG FLEXTOUCH						
N 020986 005	>A> 6899699	Jan 02, 2022	DP			
	>A> 7686786	Aug 03, 2026	DP			
INSULIN DETEMIR RECOMBINANT - LEVEMIR FLEXTOUCH						
N 021536 005	>A> 6899699	Jan 02, 2022	DP			
	>A> 7686786	Aug 03, 2026	DP			
KETOROLAC TROMETHAMINE - ACULAR LS						
N 021528 001	>A> 8648107	May 28, 2024	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LAMOTRIGINE - LAMICTAL XR						
N 022115 001	>A> 8637512	Jun 14, 2028	DP			
LAMOTRIGINE - LAMICTAL XR						
N 022115 002	>A> 8637512	Jun 14, 2028	DP			
LAMOTRIGINE - LAMICTAL XR						
N 022115 003	>A> 8637512	Jun 14, 2028	DP			
LAMOTRIGINE - LAMICTAL XR						
N 022115 004	>A> 8637512	Jun 14, 2028	DP			
LAMOTRIGINE - LAMICTAL XR						
N 022115 005	>A> 8637512	Jun 14, 2028	DP			
LAMOTRIGINE - LAMICTAL XR						
N 022115 006	>A> 8637512	Jun 14, 2028	DP			
LENALIDOMIDE - REVLIMID						
N 021880 001	8626531	Oct 23, 2020	U-1210			
	>A> 8648095	May 15, 2023	U-1216			
LENALIDOMIDE - REVLIMID						
N 021880 002	8626531	Oct 23, 2020	U-1210			
	>A> 8648095	May 15, 2023	U-1216			
LENALIDOMIDE - REVLIMID						
N 021880 003	8626531	Oct 23, 2020	U-1210			
	>A> 8648095	May 15, 2023	U-1216			
LENALIDOMIDE - REVLIMID						
N 021880 004	8626531	Oct 23, 2020	U-1210			
	>A> 8648095	May 15, 2023	U-1216			
LENALIDOMIDE - REVLIMID						
N 021880 005	8626531	Oct 23, 2020	U-1210			
	>A> 8648095	May 15, 2023	U-1216			
LENALIDOMIDE - REVLIMID						
N 021880 006	8626531	Oct 23, 2020	U-1210			
	>A> 8648095	May 15, 2023	U-1216			
LOMITAPIDE MESYLATE - JUXTAPID						
N 203858 001	8618135	Mar 07, 2025	U-1316			
LOMITAPIDE MESYLATE - JUXTAPID						
N 203858 002	8618135	Mar 07, 2025	U-1316			
LOMITAPIDE MESYLATE - JUXTAPID						
N 203858 003	8618135	Mar 07, 2025	U-1316			
LOXAPINE - ADASUVE						
N 022549 001	7052679	Oct 26, 2021	DP			
	7537009	Oct 28, 2024	DP			
	8074644	Jul 25, 2022	DP			
METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR						
N 200678 001	8628799	Jul 13, 2025	DP		>A> M-134	May 24, 2016
METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR						
N 200678 002					>A> M-134	May 24, 2016
METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR						
N 200678 003					>A> M-134	May 24, 2016
METHYLPHENIDATE - DAYTRANA						
N 021514 001	8632802	Oct 07, 2025	DP			
METHYLPHENIDATE - DAYTRANA						
N 021514 002	8632802	Oct 07, 2025	DP			
METHYLPHENIDATE - DAYTRANA						
N 021514 003	8632802	Oct 07, 2025	DP			
METHYLPHENIDATE - DAYTRANA						
N 021514 004	8632802	Oct 07, 2025	DP			
METHYLPHENIDATE HYDROCHLORIDE - CONCERTA						
N 021121 001	8629179	Jul 31, 2017	DP			
	8629179*PED	Jan 31, 2018				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2014

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
METHYLPHENIDATE HYDROCHLORIDE - CONCERTA							
N 021121	002	8629179	Jul 31, 2017	DP			
		8629179*PED	Jan 31, 2018				
METHYLPHENIDATE HYDROCHLORIDE - CONCERTA							
N 021121	003	8629179	Jul 31, 2017	DP			
		8629179*PED	Jan 31, 2018				
METHYLPHENIDATE HYDROCHLORIDE - CONCERTA							
N 021121	004	8629179	Jul 31, 2017	DP			
		8629179*PED	Jan 31, 2018				
MINOXIDIL - WOMEN'S ROGAINE							
N 021812	002					>A> NP	Feb 28, 2017
MYCOPHENOLIC ACID - MYCOPHENOLIC ACID							
A 091248	001					PC	Jul 07, 2014
NIACIN - NIACIN							
A 076250	001					PC	Mar 19, 2014
NIACIN - NIACIN							
A 076378	001					PC	Mar 19, 2014
NIACIN - NIACIN							
A 076378	002					PC	Mar 19, 2014
NITRIC OXIDE - INOMAX							
N 020845	002					M-132	Dec 21, 2013
						PED	Jun 21, 2014
NITRIC OXIDE - INOMAX							
N 020845	003					M-132	Dec 21, 2013
						PED	Jun 21, 2014
OSPEMIFENE - OSPHENA							
N 203505	001	>A> 8642079	Mar 01, 2028	DP			
OXYCODONE HYDROCHLORIDE - OXECTA							
N 202080	001	>A> 8637540	Nov 26, 2023	DP			
OXYCODONE HYDROCHLORIDE - OXECTA							
N 202080	002	>A> 8637540	Nov 26, 2023	DP			
PAROXETINE MESYLATE - BRISDELLE							
N 204516	001	>A> 8658663	Apr 06, 2029	DS DP	U-904		
PERFLUTREN - DEFINITY							
N 021064	001	>A> 8658205	Apr 20, 2019	DP			
POMALIDOMIDE - POMALYST							
N 204026	001	8626531	Oct 23, 2020		U-1361		
POMALIDOMIDE - POMALYST							
N 204026	002	8626531	Oct 23, 2020		U-1361		
POMALIDOMIDE - POMALYST							
N 204026	003	8626531	Oct 23, 2020		U-1361		
POMALIDOMIDE - POMALYST							
N 204026	004	8626531	Oct 23, 2020		U-1361		
RALTEGRAVIR POTASSIUM - ISENTRESS							
N 205786	001	7169780	Oct 03, 2023	DS DP			
		7217713	Oct 21, 2022		U-257		
		7435734	Oct 21, 2022		U-257		
		7754731	Mar 11, 2029	DS DP	U-257		
REGORAFENIB - STIVARGA							
N 203085	001	>A> 8637553	Jul 08, 2029	DS DP			
RIFAXIMIN - XIFAXAN							
N 021361	001	8642573	Oct 02, 2029		U-1481		
RIFAXIMIN - XIFAXAN							
N 022554	001	8642573	Oct 02, 2029		U-1481		
ROFLUMILAST - DALIRESP							
N 022522	001	8618142	Mar 08, 2024	DP			
SAXAGLIPTIN HYDROCHLORIDE - ONGLYZA							
N 022350	001					>A> M-134	May 24, 2016

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2014

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
SAXAGLIPTIN HYDROCHLORIDE - ONGLYZA							
N 022350 002						>A> M-134	May 24, 2016
SILDENAFIL CITRATE - REVATIO							
N 021845 001						>A> D-137	Jan 31, 2017
						>A> M-133	Jan 31, 2017
SILDENAFIL CITRATE - REVATIO							
N 022473 001						>A> D-137	Jan 31, 2017
						>A> M-133	Jan 31, 2017
SILDENAFIL CITRATE - REVATIO							
N 203109 001						>A> D-137	Jan 31, 2017
						>A> M-133	Jan 31, 2017
SIROLIMUS - SIROLIMUS							
A 201676 003						PC	Jul 15, 2014
SOFOSBUVIR - SOVALDI							
N 204671 001		8618076	Dec 11, 2030	DS DP U-1470			
		8633309	Mar 26, 2029	DS DP U-1470			
SORAFENIB TOSYLATE - NEXAVAR							
N 021923 001		8618141	Feb 11, 2023	U-1480			
TASIMELTEON - HETLIOZ							
N 205677 001	>A>	5856529	Dec 09, 2017	DS DP U-1486		NCE	Jan 31, 2019
						>A> ODE	Jan 31, 2021
TEMOZOLOMIDE - TEMODAR							
N 022277 001		8623868	Feb 21, 2023	DP			
TEMSIROLIMUS - TORISEL							
N 022088 001	>A>	5362718	Feb 15, 2019	DS DP	Y		
	>A>	5362718*PED	Aug 15, 2019				
	>A>	RE44768	Feb 15, 2019	DS DP			
	>A>	RE44768*PED	Aug 15, 2019				
THALIDOMIDE - THALOMID							
N 020785 001		8626531	Oct 23, 2020	U-1465			
THALIDOMIDE - THALOMID							
N 020785 002		8626531	Oct 23, 2020	U-1465			
THALIDOMIDE - THALOMID							
N 020785 003		8626531	Oct 23, 2020	U-1465			
THALIDOMIDE - THALOMID							
N 020785 004		8626531	Oct 23, 2020	U-1465			
TOLVAPTAN - SAMSCA							
N 022275 001	>A>	5753677	May 19, 2020	U-978			
TOLVAPTAN - SAMSCA							
N 022275 002	>A>	5753677	May 19, 2020	U-978			
TOLVAPTAN - SAMSCA							
N 022275 003	>A>	5753677	May 19, 2020	U-978			
TOPIRAMATE - TROKENDI XR							
N 201635 001	>A>	8663683	Nov 16, 2027	DS U-106			
TOPIRAMATE - TROKENDI XR							
N 201635 002	>A>	8663683	Nov 16, 2027	DS U-106			
TOPIRAMATE - TROKENDI XR							
N 201635 003	>A>	8663683	Nov 16, 2027	DS U-106			
TOPIRAMATE - TROKENDI XR							
N 201635 004	>A>	8663683	Nov 16, 2027	DS U-106			
TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST							
N 204114 001						I-678	Jan 08, 2017
						ODE	Jan 08, 2021
TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST							
N 204114 002						I-678	Jan 08, 2017
						ODE	Jan 08, 2021

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST						
N 204114 003					I-678	Jan 08, 2017
					ODE	Jan 08, 2021
TREPROSTINIL - REMODULIN						
N 021272 001	>A> 8653137	Sep 05, 2028	U-1437			
	>A> 8658694	Sep 05, 2028	U-1437			
TREPROSTINIL - REMODULIN						
N 021272 002	>A> 8653137	Sep 05, 2028	U-1437			
	>A> 8658694	Sep 05, 2028	U-1437			
TREPROSTINIL - REMODULIN						
N 021272 003	>A> 8653137	Sep 05, 2028	U-1437			
	>A> 8658694	Sep 05, 2028	U-1437			
TREPROSTINIL - REMODULIN						
N 021272 004	>A> 8653137	Sep 05, 2028	U-1437			
	>A> 8658694	Sep 05, 2028	U-1437			
UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE - ANORO ELLIPTA						
N 203975 001					>A> NP	Dec 18, 2016
VANDETANIB - CAPRELSA						
N 022405 001	>A> 8642608	Feb 06, 2022	U-1490			
VANDETANIB - CAPRELSA						
N 022405 002	>A> 8642608	Feb 06, 2022	U-1490			
VARDENAFIL HYDROCHLORIDE - STAXYN						
N 200179 001	8613950	Dec 23, 2028	DP			
ZICONOTIDE ACETATE - PRIALT						
N 021060 001	>A> 8653033	Oct 01, 2024	U-48			
	>A> 8653033	Oct 01, 2024	U-55			
ZICONOTIDE ACETATE - PRIALT						
N 021060 002	>A> 8653033	Oct 01, 2024	U-48			
	>A> 8653033	Oct 01, 2024	U-55			
ZICONOTIDE ACETATE - PRIALT						
N 021060 003	>A> 8653033	Oct 01, 2024	U-48			
	>A> 8653033	Oct 01, 2024	U-55			
ZICONOTIDE ACETATE - PRIALT						
N 021060 004	>A> 8653033	Oct 01, 2024	U-48			
	>A> 8653033	Oct 01, 2024	U-55			

Footnote:

1. Patents are published upon receipt by the Orange book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(d)(5).

2. Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. They may not be flagged with respect to other claims which may apply.

PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 34th Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at http://www.accessdata.fda.gov/scripts/cder/ob/docs/pattermsall.cfm

The current complete list of exclusivity terms is available at http://www.accessdata.fda.gov/scripts/cder/ob/docs/excltermsall.cfm